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ABSTRACT 
 
 
 
A Model for Blood Coagulation and Lysis Utilizing the Intrinsic and Extrinsic Pathways.  
 
(May 2011) 
 
Daniel Edward LaCroix, B.S., Trinity University; 
 
M.S. Texas A&M University 
 
Chair of Advisory Committee: Dr. Kumbakonam Rajagopal 
 
 
 
Blood is a complex mixture of formed cellular elements, proteins, and ions 
dissolved in a solution. It is a difficult fluid to model because it is a shear-thinning, 
viscoelastic fluid that stress-relaxes. In this study, a new mathematical model for whole 
blood is developed from a general equation for a fluid with a shear dependent viscosity. 
The model is then used as a backdrop for 28 different biochemical factors interacting to 
form a clot. The full intrinsic and extrinsic pathways are both used in the simulation; the 
inclusion of the full intrinsic pathway is something that had not been done prior to this 
work. The model is executed in one spatial direction in an infinite domain as well as 
within a rigid walled cylinder using a finite volume scheme. The rigid wall, similar to 
the new mathematical equation for blood, is an oversimplification of actual in-vitro 
conditions. The results of both simulations show the formation and dissolution of the 
clot. Sensitivity analysis is then performed in the finite domain model by adjusting the 
initial levels of factors Va and Xa. The results show that increasing the initial level of 
one or both of these factors leads to the quicker formation of a clot. 
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INTRODUCTION1 
 
  
Blood is a liquid that circulates in the body and is one of the principal 
components of the cardiovascular system. The cardiovascular system is responsible for 
the delivery and removal of nutrients, gases, and necessary components throughout the 
body.  It is made up of the heart, which acts as a pump, as well as the arteries, arterioles, 
capillaries, venules, and veins that carry and distribute blood throughout the body. Blood 
is comprised of formed cellular elements and proteins suspended in an aqueous solution. 
The formed cellular elements include erythrocytes (or red blood cells), leukocytes (or 
white blood cells), and platelets. The aqueous solution is plasma and consists of mostly 
water as well as dissolved proteins (such as fibrinogen and prothrombin) and ions (such 
as Ca+, HCO3-, etc.).  
Blood Distribution  
 Blood is pumped throughout the body by the heart. A large and complicated 
network of blood vessels is used to distribute blood. The blood vessels range in diameter 
from 2.5 cm (the aorta) to 8 µm (capillaries) (Martini et al., 2001). The pathways leading 
away from the heart are called arteries while those that usher blood on its return to the 
heart are called veins. The vessels are lined with endothelium which functions to allow 
secretion and absorption as well as protection.  A healthy endothelium will actively 
suppress unnecessary clot formation, vascular inflammation, as well as hypertrophy 
(Landmesser et al., 2004).  
                                                
1 This dissertation follows the style of Journal of Theoretical Biology. 
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It seems obvious that, without disruption, cardiac output and venous return are 
equal. Furthermore, within isolated tissues the in-flow and out-flow of blood remain 
equal. However, this does not mean that blood flows equally in arteries and veins. On 
the contrary, the two flow quite differently. Arterial blood flows in pulses while venous 
blood flow is essentially steady.  The maximum velocity, average velocity, and pressure 
are higher in arteries. These flow characteristics are logical when considering the manner 
in which blood is pumped. Arterial blood is moved by the periodic contraction of the 
heart, and while outflow from the heart is distinctly pulsatile, in smaller vessels it is 
much steadier. This is because the larger arteries expand during systole (when the heart 
contracts), storing blood. During diastole (when the heart fills with blood), the arteries 
contract, thus giving up the blood that was stored. How much a blood vessel expands 
and contracts is known as compliance. Venous blood flows smoothly because it deposits 
into atria of the heart that act as reservoirs before being pumped back into the body 
(Rajagopal and Lawson, 2007). 
Components of Blood 
Erythrocytes are actually small hemoglobin solutions bound by a flexible 
membrane. While in large pathways, red blood cells (or RBCs) are round discs with a 
diameter of about 7.7 microns and outer edges that are roughly twice as thick as the 
center (2.8 microns and 1.4 microns respectively) (Rajagopal and Lawson, 2007) . This 
discrepancy in thickness is important because as the RBCs enter smaller pathways they 
deform into a parabolic shape. The difference in thickness means that there is less 
resistance to this deformation. RBCs also contain hemoglobin, which is responsible for 
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transporting oxygen to the body. In addition to delivering oxygen, RBCs also help 
deliver carbon dioxide (mostly in the form of bicarbonate) to the lungs. Volumetrically, 
erythrocytes make up 97% of the formed elements in blood (Anand, et al. 2003). In large 
arteries, RBCs will bind together to form rouleaux (Chien et al., 1970). The shear 
thinning qualities of blood can be attributed to the disaggregation of rouleaux that form 
at low shear and the deformability of RBCs (Chien et al., 1966). Additionally, RBCs 
stay a minimum distance away from the wall due to the Fahreus-Lindqvist effect 
(Fåhreus and Lindqvist, 1931). 
In addition, recent research by scientists at the National University of Singapore 
have uncovered another function of erythrocytes: defense. Their findings state that when 
bacteria breach a red blood cell, a plethora of dangerous chemicals known as free 
radicals are released. The free radicals latch on to the bacteria and break open the cell 
wall, effectively killing the bacteria. The free radicals are also harmful to human tissue, 
but the proximity of the bacteria usually ensures that they will be the target rather than 
the endothelium. This defense mechanism has been found in horseshoe crabs as well 
which suggests that it is, evolutionarily speaking, an old defense mechanism (Kesava, 
2007). 
 Leukocytes, or white blood cells (WBC’s), are part of the body’s immune 
system, and act as the main aggressors against foreign agents. There are five different 
kinds of WBC’s: neutrophils, eosinophils, and basophils are referred to as granulocytes 
while lymphocytes and monocytes are called agranular leukocytes. Granulocytes are 
roughly 8-15 microns across while the agranular leukocytes are much bigger with sizes 
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between 15 and 25 microns (Rajagopal and Lawson, 2007). Each leukocyte serves a 
separate purpose.  
Neutrophil accumulation is associated with the immune system as well as 
inflammation and can be seen across a wide array of medical conditions from infection 
to cancer. The neutrophil combats bacterial infection as well as helping to rid the body 
of unnecessary (and therefore unwanted) extracellular deposits as well as damaged 
tissue. As neutrophils begin to fight infection they release granule enzymes, an oxidase, 
H2O2, and several lipids. The granules are mostly composed of two enzymes: the 
azurophil and the specific. The azurophil seeks out and destroys microbials while the 
specific replenishes membranes and limits reactions. It is worth noting that this 
leukocyte’s actions also cause inflammation and tissue damage to the body, which is 
normal for neutrophil accumulation (Baggiolini et al., 1989). 
How neutrophils combat microbes is especially interesting. It was previously 
thought that oxygen and oxygen reactive elements were activated to combat bacteria and 
fungi. However, this is incorrect. In actuality, electrons are pumped into the phagocytic 
vacuole (the target fungi or bacteria) which creates a charge difference across the 
membrane. As ions move across the membrane to rectify the charge difference, a path is 
created that allows the granule enzymes and superoxide to be released into the vacuole 
thus killing the target microbe (Segal, 2005). 
 While similar to neutrophils in their association with the immune system, 
eosinophils are involved in an extremely wide variety of processes. Within its function 
as a fighting agent, eosinophils are stimulated by tissue injury, infections, allergens, and 
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tumor formation. In response to stimulation, four different cytotoxic proteins are 
released. Eosinophils also discharge a wide array of cytokines responsible for 
lymphocyte proliferation and activation as well as ongoing communication with the 
lymphocytes after they have been mobilized (Rothenberg and Hogan, 2006).  
 Basophils are the least common WBC’s compromising less than 1% of 
leukocytes and have often been considered to be at best, minor and at worst, redundant. 
There exist cells in tissue that behave and perform nearly identical to basophils that are 
called mast cells (Sharon, 1998). Recent research done on mice with depleted basophils 
showed no significant effects on classic allergic reactions. In fact, it prevented the 
development of immunoglobin-E mediated chronic allergic dermatitis that is associated 
with eosinophil infiltration. Thus, basophils play an important role in the development of 
immunoglobin-E mediated chronic allergic inflammation as an initiator rather than in 
response to other immune system responses (Obata et al., 2007). Though they make up a 
small portion of WBCs, they are able to recruit assistance and call specific situations to 
the attention of the more capable elements of the immune system.  This may be the 
reason that there are such low numbers of basophils found within blood: they are merely 
intended to alert more capable leukocytes as well as act as reinforcements to the battle 
being waged by mast cells. 
 Lymphocytes can be broken down into three groups: T-cells, B-cells, and natural 
killer (NK) cells. Research into these elements yields a veritable library of information 
that delves deep into specifics surrounding their origin, role within the immune system, 
and relationship with elements that are outside the scope of this paper. As is, a general 
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overview of each cell and its variations will be discussed.  
 T-cells are so named because they are formed primarily in the Thymus. All T-
cells have several receptors on their membrane referred to as T-cell receptors. The 
receptors may be comprised of an α-β chain or a δ-γ chain, but not both. A T-cell only 
contains one type of receptor that is repeated. Within humans, α-β cells make up 
between 85 and 95% of all T-cells. There are three main types of T-cells; T-cytotoxic, T-
helper, and T-suppressor, and each serves a different purpose within their function as a 
T-cell. T- cytotoxic cells are sometimes called effectors because they effectively kill 
target cells. In order to do this, the T-cytotoxic cell bonds to the MHC class I complex of 
a cell with an unrecognizable antigenic determinant. T-helper cells, as their name 
implies, encourage the immune system response. T-suppressor cells do the opposite and 
work to dampen the immune system response. Both T-helper and T-suppressor work 
through direct contact with other cells as well as by the secretion of soluble molecules 
that impact the function of other cells (Sharon, 1998).  
 B-cells perform a similar function as T-cells, but in a different way. The B-cell 
antibody is shaped like a “Y”. The branches at the top are known as the Fab region, and 
provide two sites to bind antigens. The base part of the “Y” is referred to as the Fc 
region and is responsible for effector and transport functions. It doesn’t destroy the 
antigen itself, but rather clings to the target cell and rallies other soluble proteins as well 
as specific effector cells to its position. As such, B-cells often become the targets of T-
cells. Both T-cells and B-cells develop memories to specific antigens. The result is that 
in addition to the primary immune system response, there is also a bigger and faster 
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(thus better) secondary antibody response. The combination of the B- and T-cell memory 
often means that re-exposure to a pathogen will not result in disease (Sharon, 1998). 
This is mostly likely the main reason that seasonal ailments are only contracted once.  
 Natural Killer cells derive their name from their ability to kill host cells. NK-cells 
are similar to B-cells and especially similar to T-cells, but lack a receptor mechanism 
similar to either. In addition, on the average, NK-cells are slightly larger than the other 
two types of lymphocytes (9-15 micrometers opposed to 6- 15 micrometers 
respectively). An NK-cell has two receptors that, in effect, serve as the conscious of the 
cell. The activation receptor binds to ligands of a potential target and triggers the killing. 
The inhibitory receptor binds to the MHC class I molecules and, if engaged, transmits a 
protective signal that blocks the activation, thus preserving the target cell from 
destruction. Some pathogens may decrease the MHC class I expression in host cells as 
an effective way to avoid targeting by T-cytotoxic cells, but this results in targeting by 
NK-cells (Sharon, 1998). As the example shows, it is important to have more than one 
way to dispose of foreign cells. As an antigen adjusts to be more resistant to one 
lymphocyte, it often becomes more vulnerable to another.  
 The platelet is the final cellular element of blood to be discussed. Platelets are 
made in bone marrow, and their levels in blood are monitored and determined by the 
spleen. The average life span of a platelet is seven to ten days, and under steady state 
conditions, roughly two thirds of that will be spent in circulation and the other third will 
be spent in the spleen (Rajagopal and Lawson, 2007). The main function of platelets is to 
repair severed blood vessels. With regards to distribution, platelets drift towards the 
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wall; thus, they are not evenly dispersed throughout a blood vessel radially (Eckstein and 
Belgacem, 1991).  
 The cellular matter discussed to this point accounts for roughly 44% of whole 
blood; plasma accounts for the remaining 56%. The majority of plasma is water, which 
makes up 92-93%. The remaining 7-8% is a myriad of proteins and various ions (Anand 
et al., 2003). Among these are the factors critical in the formation of a clot, including but 
not limited to the inactivated and activated forms of factors V, VII, VIII, IX, X, XI, XII, 
as well as those that work against clotting such as Protein C, Tissue Factor Pathway 
Inhibitor, and Anti-thrombin III.  
 In mechanical terms, blood is a difficult fluid to model. It is primarily made up of 
plasma, a newtonian fluid, however, the work of Chien et al. (1966) shows that blood is 
shear-thinning. This description also doesn't encompass the full complexity of blood. 
Thurston (1972) showed that not only is blood viscoelastic, but that it also stress-relaxes.  
Blood Coagulation  
 During times of vascular damage, a clot is formed in a process known as 
thrombosis to prevent blood loss. Blood coagulation is an involved combination of 
positive and negative feedback mechanisms. During normal flow, the negative feedback 
factors dominate to halt the unnecessary formation of blood clots. When the blood vessel 
wall (or endothelium) is ruptured, it triggers three pathways, often referred to as 
Virchow's Triad (Anand et al., 2003). The first, is initiated by the activation of platelets. 
The second, the extrinsic pathway, so called because it involves factors not found in 
whole blood, is initiated by the release of tissue factor (TF) by the subendothelium. The 
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final pathway is the intrinsic pathway because it is triggered by factors found in whole 
blood. The final result of thrombosis is a fibrin net or mesh to which platelets adhere, 
thus forming a thrombotic plug. Two graphic images depicting the extrinsic and intrinsic 
pathways are presented in Fig. 1 and 2. 
 The platelet pathway is characterized by the activation of blood platelets. When 
activated, a platelet changes from a smooth disc into a spindly orb. Platelets can be 
activated by high shear stress as well as by chemical agonists. After the vessel wall is 
damaged, platelets attach to von Willebrand factor, collagen, and fibronectin located in 
the sublayer of the endothelium. As the platelets bond with the von Willebrand factor, 
they begin to resist the shear stress imparted by the passing blood. Additionally, as the 
platelet bonds to the collagen of the wall, platelet receptors are activated that initiate 
thrombaxane A2 formation as well as the release of storage granules (including ADP). 
The thrombaxane A2 and ADP are recognized by receptor sites on passing platelets, 
which are then activated and change shape to form an aggregate around the established 
platelets. The granules also cause the release of procoagulant phospholipids to the 
platelet surface which act to accelerate the thrombus formation by acting as catalysts and 
speeding up reactions (Rand et al., 2003). 
 The extrinsic pathway is triggered by the release of tissue-factor (TF) from the 
subendothelium following rupture of the endothelium. TF binds with factor VIIa to form 
the TF-VIIa complex, which in turn activates factors IX and X to IXa and Xa, 
respectively (Anand et al., 2008).  The extrinsic pathway is counteracted by tissue factor 
pathway inhibitor (TFPI) and antithrombin-III (ATIII). 
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 The intrinsic pathway is activated by factor XII (or Hageman factor) coming into 
contact with a negatively charged surface, such as that found in the subendothelium. For 
this reaction, high molecular weight kininogen (HMWK) is present as a cofactor.  When 
factor XII is activated, it splits into equal amounts of α-XIIa and β-XIIa (Revak, 1977). 
These two factors, with independent rate constants, convert pre-kallikrein (preK) to 
kallikrein (kalli), which serves to activate more factor XII. This positive feedback loop 
serves as the main form of factor XII activation and greatly increases the amount of 
factor XIIa being produced (Tankersley and Finlayson, 1984). Factor XIIa activates XI 
to XIa, and XIa then activates IX to IXa. Protein C1-inhibitor (C1INH) serves to inhibit 
XIIa, kallikrein, and XIa. 
 After the intrinsic and extrinsic pathways are initiated, they converge at the 
activation of factor X. Together, Xa and Va make up the complex prothrombin, which 
converts II to IIa. As thrombin production continues, it converts fibrinogen (I) to fibrin 
(Ia). The strands of fibrin bind with platelets as the clot begins to form. As thrombin 
(and fibrin) production continue, the extravascular space above the damaged 
endothelium becomes filled. Now fully developed, the clot covers the damaged area and 
prevents blood from making further contact as well as preventing more pro-coagulant 
zymogens from reaching the extra-vascular compartment. Within the intravascular 
compartment, two different mechanisms serve to inhibit enzymes from escaping the clot. 
The first is Antithrombin III-Heparin Sulfate complex (HS-ATIII), which serves to 
inactivate IIa, Xa, and IXa. The second is Activated Protein C (APC) which is formed 
when Protein C binds to thrombin bound to endothelial thrombomodulin. APC 
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suppresses the formation of thrombin and fibrin by inactivating Va and VIIIa.  
 The breakdown of the clot, or fibrinolysis, is initiated by the same thrombin that 
promotes clot development. Thrombin (IIa) as well as fibrin (Ia) induce endothelial cells 
within the intravascular compartment to release tissue-plasminogen activator (tPA). 
Plasminogen (PLS) binds with tPA and Ia to form a complex that converts plasminogen 
to plasmin (PLA), the main degradation agent of fibrin (Ia). As the fibrin mesh breaks 
down, more binding sites are revealed to convert more PLS to PLA, thus advancing the 
dissolution of the clot. A higher concentration of PLA will result in a faster rate of 
degradation. Fibrinolysis is complete when the clot is completely dissolved. Any 
remaining plasmin is deactivated by α2-antiplasmin (α2 AP).   
 The activations (and subsequent inactivations) presented above can be 
mathematically modeled in various ways. The first is with Michaelis-Menten kinetics, in 
which the reaction rate is dependent upon the maximum value of the reaction as well as 
the amount of substrate available. A reaction following Michaelis-Menten kinetics has 
the form: 
[ ] [ ]
[ ]S+K
SV=
t
B
m
max
∂
∂          (1) 
where the change in concentration of some substance B is affected by Vmax, the 
maximum rate of the  reaction, Km, the inverse of enzyme availability, and S, the 
concentration of substrate. A first order reaction has the form: 
[ ] [ ]Bk=
t
B
1∂
∂
  
        (2) 
where B represents the concentration of a substance that changes with respect to the 
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activation (or deactivation) constant and the concentration of B present. Here, k1 has 
units of s-1. The final mode of activation considered is second order, following: 
[ ] [ ][ ]BAk=
t
B
2∂
∂          (3) 
 For reactions of this form, the rate of change in the concentration of B is dependent on 
the concentrations of both A and B. For this reaction, k2 has units of s-1mol-1.  
Coagulation Disorders 
 Disorders that arise surrounding the formation of clots are plentiful, and have 
been linked to a myriad of medical problems including, but not limited to, myocardial 
infarcation (heart attack), stroke, and ischemia. Pulmonary thromboembolism is an 
especially grave problem arising from clotting disorders, causing 5-10% of all hospital 
deaths (Goodnight and Hathaway, 2001). Clotting disorders can be broken into two 
groups: hemorrhagic and thrombotic. Hemorrhagic disorders are characterized by the 
body not developing a clot in response to vascular damage. Thrombotic disorders cause 
the body to form unnecessary clots. An excess or deficiency of a specific factor within 
the clotting cascade can have adverse effects on thrombosis. 
 Deep veinous thrombosis (DVT) and pulmonary thromboembolism are two of 
the major problems that may arise from a hypercoagulable state. DVT is characterized 
by a clot forming in a deep (or large) vein, thus blocking blood flow to parts of the body. 
Additionally, the clot could become dislodged, thus causing an embolism. Typically, 
these two conditions are caused by an excess of clotting factors, clotting factors in a 
mutant and hyperactive state, an insufficient amount of anti-coagulants, or anti-
coagulants in a mutant and ineffective form. The most common forms are Factor V 
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Leiden, mutant Prothrombin, Protein C deficiency, Protein S deficiency, and ATIII 
deficiency. Endothelial dysfunction could also be considered a risk. Treatment in most 
cases is done by administering anticoagulants (Anand et al., 2003). 
 Individuals with a deficiency of Factor XII do not show abnormal bleeding. 
However, there is an inverse association between myocardial infarcation and high levels 
of XII which suggests that there is a protective effect for elevated concentrations. In its 
activated form, XIIa, heightened levels have been associated with an increased risk for 
coronary heart disease while low levels pose a risk of coronary artery disease and stroke 
in middle aged men (Gailani and Renné, 2007). 
 A deficiency of factor VIII, IX, or XI results in hemorrhagic disorders known 
haemophilia A, B, and C, respectively. Typically, the factor in question is at a level 70% 
below normal. Severe cases of haemophilia A and B are associated with hemorrhage into 
joints and muscles, as well as soft tissue bleeding that can be life threatening. 
Haemophilia C is usually milder, characterized by trauma or soft tissue related 
hemorrhage, primarily with tissue that has high fibrinolytic activity (Gailani and Renné, 
2007). Typically, the disorder is treated by the intravenous replacement of the deficient 
factor (Goodnight and Hathaway, 2001). 
 Elevated levels of factors VIII, IX, and XI can prove to be equally problematic. 
Studies have shown that individuals with VIII above the upper limit of normal have 
roughly 5 times the possibility of venous thromboembolism. Similarly, levels of IX and 
XI in the top 10% have twice the risk of thromboembolism. High levels of factor XI 
have also been associated with an increased risk of heart attack, stroke, and ischemia 
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(Gailani and Renné, 2007).  
 Thrombocytopenia, or low platelet count, is a hemorrhagic disorder. This may be 
caused by a lack of platelet synthesis, improper regulation by the spleen, or excessive 
platelet destruction (Anand et al., 2003). The goal of treatment is not to achieve normal 
levels, but rather to achieve adequate levels; steroids often have a positive response. In 
adult cases, if all other treatments fail, a spleenectomy may be done (Goodnight and 
Hathaway, 2001). Platelet dysfunction, though different than thrombocytopenia, may 
have similar results. The administering of drugs for other afflictions may inactivate 
thromboxane A2 and/or ADP release. This results in the reduction of platelet adhesion 
and recruitment (Anand et al., 2003). 
  Von Willenbrand's disease is a genetic affliction causing a qualitative or 
quantitative shortfall of von Willenbrand factor (vWF). As has already been discussed, 
vWF plays an important role in the platelet adhesion to blood vessel walls, but it is also a 
carrier protein for factor VIII. Von Willenbrand's disease is characterized by 
mucocutaneous bleeding, and has several variations with varying effects (Goodnight and 
Hathaway, 2001).  
 Disseminated Intravascular Coagulation (DIC) is a complex entity that may have 
many stimuli. It is characterized by early formation of intravascular thrombi followed by 
subsequent coagulation factor depletion and augmented fibrinolysis; the end result is 
excessive bleeding. Thus, DIC is both a thrombotic and hemorrhaging disorder. It may 
be a complication caused by sepsis or trauma. Treatment depends on the stage it is 
recognized and often attempts to treat the underlying cause. Early thrombotic DIC is 
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countered by administering anticoagulants to prevent thrombus formation and also 
prevent coagulation factor depletion. Later stages of DIC, or bleeding DIC, is treated 
with agents to either augment coagulation or inhibit fibrinolysis (Anand et al., 2003). 
 The most popular anti-coagulant drugs are Heparin and Warfarin. Heparin works 
by impairing platelet function and irreversibly inactivating factors IXa, Xa, and XIa, all 
three of which are found in the intrinsic pathway. Warfarin deactivates factors VII, IX, 
X, and II, which are found in the intrinsic and extrinsic pathways. In order to effectively 
model the effects of either of these anticoagulants, the inclusion of the full intrinsic 
pathway is required. 
 A complete blood coagulation model would include the full scope of 
hemodynamics and the three major pathways of coagulation. The model could then be 
put to use in several capacities. A well-conceived and well executed model could replace 
experiments as well as simulate potential disturbances to clotting hemodynamics caused 
by disease or medication. Further, the model could be used in the design of implantable 
stents, ventricular assist devices, and artificial hearts. 
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LITERATURE REVIEW 
 
 
Whole Blood Literature Review 
 A variety of models for whole blood have been formulated with varying 
complexity. In 1966, experiments by Chien et al. showed that for whole blood, shear rate 
and viscosity do not have a linear relationship i.e. whole blood is non-newtonian. 
Walburn and Schneck (1976) posed a power law model based upon the hematocrit as 
well as a calculated quantity of fibrinogen and globulins. However, the model shows a 
decreasing viscosity at higher shear rates when whole blood is considered to behave as a 
newtonian fluid (Pedley, 1980). A Casson fluid model is presented by Fung (1997) and 
follows the general shape of experimental data, however it overestimates viscosity at 
high shear rates (Johnston et al., 2004). In 1991, Cho and Kensey presented a Carreau 
model that corrected this overestimation and was relatively accurate. Luo and Kuang 
(1992) presented a three-parameter constitutive equation that was a modification of 
Casson's equation and is adaptable over a wider range of shear rates.  The apparent 
viscosity for all of these models is presented in Appendix C. 
 Other models have been put forth more recently. In 1996, Yeleswarupu proposed 
a generalization of an Oldroyd-B fluid model that fit data better than other models used 
at the time (Anand and Rajagopal, 2004).  However, the model did not have a 
thermodynamic basis, something that Rajagopal and Srinivasa (2000) corrected. In 2004, 
Anand and Rajagopal further advanced this model to more accurately fit experimental 
data. Because the model put forth by Anand and Rajagopal represents the culmination of 
the Oldroyd-B fluid models, it is also presented in Appendix C. 
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 While the Walburn and Schneck model and Casson model use hematocrit, no 
other model uses constituents within the blood to adjust the viscosity. Although blood is 
a mixture of various cells, proteins, ions, glycoproteins, and platelets, all of the models 
discussed herein model blood as a continuum.  
Clotting Model Literature Review 
 At a similar time, papers authored by MacFarlane (1964) and Davie and Ratnoff 
(1964) showed the coagulation pathways as enzyme cascades. As a result, mathematical 
models have emerged to illustrate and predict coagulation processes. The first such 
model was by Levine (1966) who mathematically characterized general enzyme 
cascades using the work of MacFarlane (1964) and Wald and Bownds (1965) as guides. 
 In 1984, Nesheim et al. designed a program to mathematically simulate the 
functional properties of prothrombin using experimentally determined kinetic 
parameters. Simulations were carried out for a given set of initial concentrations of 
reaction components. The distribution of enzymatic components and substrates were 
then calculated from the distribution, fractional binding, and local and bulk 
concentrations. The results were then compared with experimental data. 
 In 1986, Nemerson and Gentry proposed a model showing that the activation of 
factors IX and X is predicated on their interaction with tissue factor and factor VIIa. 
Equations were derived to show that product formation is accompanied by the release of 
the enzyme activator complex. The model was verified by experiments using bovine 
tissue factor.  
 Khanin and Semenov (1989) proposed a non-linear model of the activation using 
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factors VIII, X, V, II, I, and their activated forms. The model is notable because it shows 
the reciprocal activation of IIa and Va. Deactivations of the factors used were also taken 
into account. The majority of the activation (and deactivations) were modeled as first 
order, only IIa was modeled using Michaelis-Menten kinetics. 
 Jones and Mann (1994) proposed a more involved model showing the full 
extrinsic pathway to activation utilizing TF, VIIa, IX, IXa, X, Xa, V, Va, II, and IIa. The 
activation and deactivation kinetics were modeled using first and second order rate 
constants. The end result is 18 first order differential equations. The thrombin, Xa, and 
IXa production levels were compared to experimental data. The model stops short of 
showing fibrin activation and thus clot development. It also neglects to include the 
inhibiting factors of the extrinsic pathway. 
 In 1996, Zarnitsina et al. proposed a model that included the formation of fibrin 
and also incorporated the anticoagulation effects of Activated Protein C (APC). The 
model incorporates Michaelis-Menten, first order, and second order kinetics to show the 
interactions of factors IX, IXa, VIII, VIIIa, V, Va, X, Xa, II, IIa, I, Ia, and APC. The end 
result is a spatial model of eight differential equations and one ordinary differential 
equation. The model set a boundary condition for factor IXa only. Though the authors 
call it a model of the intrinsic pathway, the factors most associated with the intrinsic 
pathway (XII, XIIa, XI, XIa) were not included. 
 The extrinsic pathway was modeled in more detail by Kuharsky and Fogelson in 
2001. Though fibrin is not included, the full extrinsic pathway along with the inhibitors 
TFPI, APC, and ATIII and platelet interactions are modeled. The model also 
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incorporates flow and adjusts the flux of components based upon boundary layer 
thickness. The final model is a system of 59 ordinary differential equations.  
 Bungay et al. (2003) modeled the extrinsic pathway and its inhibitors in a static 
fluid environment. The model is significantly different because it differentiates between 
fluid and lipid bound factors and complexes. Thus, reactions take place between factors 
and complexes both in the fluid and on the lipid membrane. The result is 73 ordinary 
differential equations using first and second order kinetics.  
 Anand et al. (2003) modeled the extrinsic pathway in a generalized oldroyd-B 
fluid with flow in one spatial direction. The model incorporates Michaelis-Menten as 
well as first and second order reaction kinetics in 25 coupled convection-diffusion-
reaction partial differential equations. It is a two phase model with the clot behaving as 
fluid with much higher viscosity. Platelets are included in the model as protein binding 
sites as well as catalytic surfaces. The intrinsic pathway was not included, nor was the 
fibrinolysis of the clot.  
 Bodnar and Sequiera (2008) modeled the formation of a clot using only the 
extrinsic pathway in a medium sized artery. A shear-thinning fluid was used for blood, 
23 partial differential equations were used to model the biochemical reactions taking 
place, and only the growth of the clot was shown.  The model oversimplified the level of 
TF-VIIa in the boundary conditions, failed to show the lysis of the clot, did not include 
the intrinsic pathway, and used a lower velocity than is found in-vivo for the size of the 
artery modeled. 
 The most pertinent work to this study was done by Anand et al. (2008). The 
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model showed the formation and lysis of a clot using 23 partial differential equations to 
mimic the full extrinsic pathway. The clot was modeled in one dimensional direction in 
quiescent plasma over a thrombogenic pane. Thrombin production results compared 
favorably with experimental data from Butenas et al. (1999). The model was then used 
to look at Protein C and ATIII deficiencies and their effects on initiation time as well as 
the size of the clot. The model failed to include the intrinsic pathway.   
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PRELIMINARIES 
 
 
 This section will discuss a few of the concepts from continuum mechanics that 
will be used to develop the model. 
For a body B, let ƙR(B) be the reference configuration and ƙt(B) be the current 
configuration at some time t. Now, a sufficiently smooth motion, χ, may take place. The 
motion is a one-to-one mapping such that for every point X є ƙR(B) there is a point x є 
ƙt(B). Thus,   
 𝒙 =  𝝌 𝑿, 𝑡      𝑜𝑟   𝑿 =  𝝌!𝟏(𝒙, 𝑡)       (4) 
Any property of the body, φ, can be expressed as: 𝜑 =  𝜑 𝑿, 𝑡 =  𝜑(𝒙, 𝑡)        (5) 
The velocity, v, and acceleration, a, are defined as: 𝒗 𝑿, 𝑡 =   !𝝌!"           (6) 𝒂 𝑿, 𝑡 =   !!𝝌!!!           (7) 
Additionally, the deformation gradient, F, and the Cauchy-Green left and right stretch 
tensors, respectively are: 
 
X
xF
∂
∂=                 (8) 
 
T=FFB           (9) 
 
FFC T=           (10) 
 
Now, the velocity gradient, L, can be defined as: 
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( )v
X
vL grad==
∂
∂          (11) 
 
The symmetric part of the velocity gradient, D, is: 
 
D=
1
2
L+L
T( )          (12) 
 
Because blood will be treated as an incompressible fluid, the trace of the symmetric part 
of the velocity gradient will be zero. 
tr D( )= 0           (13) 
 
The equation governing the flow and reaction of each of the terms used in the 
biochemical aspect of the model is: 
! C
i[ ]
!t
+div C
i[ ]v( )= div Di
! C
i[ ]
!x
"
#
$
%
&
'+Gi;i =1,...,28            (14) 
 
where Ci is the concentration of a specific constituent, Di is the diffusion term 
correlating to the constituent, v is the velocity field of the fluid (for this work, zero), x is 
the spatial dimension, and Gi is the reaction term responsible for the production or 
depletion of the constituent in question. Each constituent is assumed to exist at every 
point and to not affect the overall flow rate.  
 The balance of mass, linear momentum and angular momentum are defined as: 
( ) 0=ρdiv+
Dt
Dρ v          (15) 
 
div T( )+!b= !
Dv
Dt
         (16) 
 
T=TT           (17) 
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where ρ is the density, v is the velocity field, t is time, b is the body force, and T is the 
stress tensor.  It should be stated that the balance of angular momentum is in the absence 
of internal body forces.  
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MODEL DESCRIPTION 
 
Whole Blood Constitutive Equation  
 As has already been discussed, blood is a shear-thinning viscoelastic fluid that 
stress-relaxes. The new constitutive equation can account for the shear-thinning 
viscosity, but fails to account for the stress-relaxation or elastic properties. Though flow 
is not taken into account in the biochemical portion of this work, the new equation for 
blood can be incorporated in future models. The stress for the new model is taken from 
Malek et al. (1995): 
 𝑻 = −𝜋𝑰+  𝜇! 1+ 2𝐃 ! !!!! (2𝐃)       (18) 
 
where π is the pressure, I is the identity tensor, and D maintains its previous meaning. 
By setting p to a value less than two, shear-thinning fluids can be modeled. For this 
work, the equation was modified slightly to be: 
 𝑻 =  −𝜋𝑰+  𝜇(𝑐)(1+ 𝛼 𝐃 𝟐)!(𝐃)      (19) 
 
where µ(c) is a function based upon the amount of fibrin present in the blood, while α 
and m are constants. As levels of fibrin increase, the viscosity of blood also increases. 
When the level of fibrin within the blood reaches a critical level, for this work 350 nm, a 
clot is considered to be formed. The critical level is adapted from Ovanesov et al. 
(2002). At this concentration in the model, the viscosity will be 100 times that of normal 
blood.  
 The values for µ(0), α, and m are calculated based upon the experimental data 
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from Chien et al. (1966). The raw data points were extrapolated using Engauge Digitizer 
4.1. By establishing axes and then clicking on individual plot points, the program 
accurately estimates values for raw data points. The function for µ(c) was then calculated 
assuming a parabolic relationship between the initial value and the critical value. 
 When solving for general viscosity in a rotary viscometer, the symmetric part of 
the velocity gradient is the shear rate. For whole blood, maintaining µ and α as already 
presented, eq 19 becomes: 
      
        (20) 
 
where µ  is the generalized viscosity and γ  is the shear rate. Using MATLAB, the 
values for the constants were estimated and refined to match the raw data. The 
coefficient of determination was then used to calculate the accuracy of the fit. The 
coefficient of determination was found using: 
tot
err
SS
SS=R −12          (21) 
 
where 
 
( )∑ − 2iierr fy=SS          (22) 
 
and 
 
( )∑ − 2yˆy=SS itot          (23) 
 
Here, yi is the value obtained experimentally, ŷ is the mean of all experimental values, 
and fi is the predicted value using eq. 20. 
 
( ) ( )
m
γα+µ=µ 


 2
2 
10 
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Clotting Model 
 The aim of this work was to create a model that is more comprehensive in its 
approach while minimizing the increase in complexity. A full clotting model would 
include all three pathways of Virchow's Triad: the platelet pathway, the extrinsic 
pathway, and the intrinsic pathway. With respect to modeling, the platelet pathway 
involves many different elements interacting in various ways. Among these are: the 
activation of platelets by shear stress, activation of platelets by chemical agents, platelet 
transport in flowing blood, platelet-platelet and platelet-surface interaction mechanics 
and kinetics, and the interplay between the platelet pathway and the other pathways of 
coagulation. For these reasons, the platelet pathway was neglected in this work. 
 The in vitro case is considered where blood is exposed to a negatively charged 
surface as well as a layer of subendothelial proteins. This initiates both the intrinsic and 
extrinsic pathways of coagulation, which then proceed along the pathway of activation. 
The end result is a fibrin scaffold to which platelets would adhere over the thrombogenic 
layer. The formation of the clot then initiates a series of reactions that result in the 
breakdown of the clot. 
 The 28 equations for the production and depletion of the separate constituents are 
all of the form: 
[ ] [ ]( ) [ ] iiiii G+
CDdiv=Cdiv+
t
C






∂
∂
∂
∂
x
v       (24)  
  
 
Here, Ci is the concentration of each, Di is the diffusion term correlating to that 
constituent, v is the velocity field of the fluid, x is the spatial dimension, and Gi is the 
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reaction term responsible for the production or depletion of the constituent in question. 
Because the velocity flow field is zero for this work, eq 21 reduces to: 
[ ] [ ]
i
i
i
i G+)Cdiv(D=
t
C
x∂
∂
∂
∂         (25) 
Figures 1 and 2 show a graphical representation of the reactions. The kinetic constants 
for the reactions can be found in Table 1, while the diffusion coefficients can be found in 
Table 2. The diffusion coefficients are calculated at 37˚ C using a correlation found in 
Young et al. (1980).  
 The 28 constituents chosen for this model are: fibrinogen (I) and fibrin (Ia), 
prothrombin (II) and thrombin (IIa), V and Va, VIII and VIIa, IX and IXa, X and Xa, 
tenase (IXa-VIIIa-PL- written as Z), prothrombinase (Xa-Va-PL- written as W), XI and 
XIa, XII and XIIa (also known as Hageman factor), prekallikrein and kallikrein (preK 
and Kalli), Antithrombin-III (ATIII), Protein C (PC) and Activated Protein C (APC), 
Tissue Factor Pathway Inhibitor (TFPI), C1-Inhibitor (C1INH), α1-Antitrypsin (α1AT ), 
Tissue Plasminogen Activator (tPA), Plasminogen (PLS) and Plasmin (PLA) and α2-
Antiplasmin (α2AP). Additionally, the TF-VIIa complex and endothelial cell tPA 
generation are taken into account in the boundary conditions. While not a complete list, 
these factors capture the salient features of the formation, propagation, and dissolution of 
a blood clot according to biochemical and clinical studies.  
 The equations for the reactions governing the production and depletion of each 
constituent are shown below. They are based upon experimental data from a multitude of 
sources. Zymogens are depleted by being activated into its corresponding active enzyme. 
The activated enzyme is then depleted by inactivation. Following convention, the terms 
28 
 
 
in brackets refer to a concentration of the factor located therein. The equations are:
[ ][ ]
[ ]
[ ][ ]
[ ]
[ ] [ ] [ ] [ ]( )C1INHhATαhATIIIhXIa
XI+K
XIXIIak+
XI+K
XIIIak=G 11a-CInhXIa ++− 111L111A3
12aM
12a
11M
11
  
(26) 
            
[ ][ ]
[ ]
[ ][ ]
[ ]XI+K
XIXIIak+
XI+K
XIIIak=G
12aM
XI
12a
11M
11 −−       (27)  
 
[ ]
[ ]
[ ][ ]
[ ]XII+K
XIIkallik+
XII+K
XIIk=G
kalliM
kalli
12M
12
XII
−−       (28) 
 
[ ]
[ ]
[ ][ ]
[ ]XII+K
XIIKallik+
XII+K
XIIk=G
kalli
kalli
XIIa
12
12   
   [ ] [ ] [ ] [ ]( )APαhATIIIhC1INHhhXIIa αAPATIII12a-PCI 212 −−−−  (29)  
 
 
[ ][ ]
[ ]
[ ][ ]
[ ]PreK+K
PreKXIIak+
PreK+K
PreKXIIak=G
PreKBM
PreKB
PreKAM
PreKA
preK
−−     (30)  
 
[ ][ ]
[ ]
[ ][ ]
[ ]
[ ]Kallih
PreK+K
PreKXIIak+
PreK+K
PreKXIIak=G kalli
PreKBM
PreKB
PreKAM
PreKA
kalli −    (31) 
 
[ ] [ ] [ ]( )XIah+XIIahC1INH=G 11a-CInh12a - CInhC1INH −      (32) 
 
[ ][ ]
[ ]
[ ][ ]ATIIIIXah
IX+K
IXXIak=GIXa 9
9M
9 −        (33) 
 
[ ][ ]
[ ]IX+K
IXXIak=GIX
9M
9−          (34) 
 
[ ] [ ][ ]
dZK
IXaVIIa=Z          (35) 
 
[ ][ ]
[ ]
[ ][ ] [ ][ ]XaTFPIhATIIIXah
X+K
ZVIIIak
=G TFPIXa −− 10
10M
10     (36) 
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[ ][ ]
[ ]X+K
ZVIIIak=GX
10M
10−          (37) 
 
[ ] [ ][ ]
dWK
XaVa=W          (38) 
 
[ ][ ]
[ ]
[ ][ ]ATIIIIIah
II+K
IIWk=GIIa 2
2M
2 −        (39) 
 
[ ][ ]
[ ]II+K
IIWk=GII
2M
2−          (40) 
 
[ ][ ]
[ ]
[ ] [ ][ ]
[ ]VIIIa+H
VIIIaAPChVIIIah
VIII+K
VIIIIIak=G
C8M
C8
VIIIa −− 8
8M
8      (41) 
 
[ ][ ]
[ ]VIII+K
VIIIIIak=GVIII
8M
8−         (42) 
 
[ ][ ]
[ ]
[ ] [ ][ ]
[ ]Va+H
VaAPChVah
V+K
VIIak=G
C5M
C5
Va −− 5
5M
5       (43) 
 
[ ][ ]
[ ]V+K
VIIak=GV
5M
5−          (44) 
 
[ ][ ]
[ ]
[ ][ ]ATαAPCh
PC+K
PCIIak=G PC
PCM
PC
APC 1−       (45) 
 
[ ][ ]
[ ]PC+K
PCIIak=G
PCM
PC
PC
−         (46) 
 
[ ] [ ] [ ] [ ] [ ] [ ]( )XIIah+XIah+IIah+Xah+IXahATIII=G ATIII11A3210ATIII 9−   (47)  
 
[ ][ ]XaTFPIh=G TFPITFPI −         (48) 
 
[ ][ ] [ ][ ]ATαXIahATαAPCh=ATG PCα 111L111 −−
     (49) 
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[ ][ ]
[ ]
[ ][ ]
[ ]Ia+H
IaPLAh
I+K
IIIak=GIa
1M
1
1M
1 −        (50) 
 
[ ][ ]
[ ]I+K
IIIak=GI
1M
1−          (51) 
 
0=GtPA           (52) 
 
[ ][ ]
[ ]
[ ][ ]
[ ]
[ ][ ]APαPLAh
PLS+K
PLSXIIak+
PLS+K
PLStPAk=G PLA
PLA
PLA
PLAM
PLA
PLA 2
12aM
12a −
−
−    (53) 
 
[ ][ ]
[ ]
[ ][ ]
[ ]PLS+K
PLSXIIak
PLS+K
PLStPAk=G
PLA
PLA
PLAM
PLA
PLS
12aM
12a
−
−−
−      (54) 
  
 
[ ] [ ] [ ]( )XIIah+PLAhAPα=APG αAPPLAα 22 −
      (55) 
 
The equations thus far not included in previous models, and worthy of discussion, 
include 28, 29, 30, 31, and 32. These are the equations for the generation and depletion 
of factors XII, XIIa, prekallikrein, kallikrein, and C1-Inhibitor. Other equations have 
been adjusted as necessary to reflect the inclusion of these five species.  
 The activation of XIIa is triggered by contact with a negative surface. However, 
the work of Tankersley and Finlayson (1984) shows that, “...reciprocal activation is the 
predominant mode of factor XII activation in normal plasma.” The auto-activation and 
activation by kallikrein both follow Michaelis-Menten kinetics. The initial activation 
uses high molecular weight kininogen (HMWK) as a cofactor. Here, it is assumed that 
there is plentiful HMWK for the reaction. When factor XII is activated, it splits into 
equal amounts of α-XIIa and β-XIIa. For this reason (and convenience), the single 
concentration of XIIa may be used with different kinetic constants to show its effect on 
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other species. Factor XIIa also contributes to the production of PLA following 
Michaelis-Menten kinetics, thus accelerating the process of fibrinolysis (Schousboe et 
al., 1999). 
 Factor XIIa is inactivated by ATIII, C1INH, and α2AP following second order 
kinetics (Pixley et al. 1985). The inactivation constant for ATIII was obtained in the 
presence of saturating concentrations of heparin. The literature makes no distinction 
between the two forms of activated factor XII; therefore the inactivation is attributed to 
both.  
 Both forms of activated factor XII have an effect on kallikrein production with 
independent kinetic activation rates on prekallikrein. The production of kallikrein due to 
α-XIIa and β-XIIa follows Michaelis-Menten kinetics. This is reflected in equations 30 
and 31. The inactivation follows pseudo-first order kinetics (Van der Graaf et al., 1983). 
Here, it is modeled as a first order reaction. 
 Protein C1-Inhibitor has been included because of its effect on the inactivation of 
factors XIIa, XIa, and Kallikrein. Though its concentration is not included in the 
deactivation of Kallikrein, the first order rate constant for Kallikrein decreases 
substantially in C1INH deficient plasma (Van der Graaf et al., 1983). Factors XIIa and 
XIa are both deactivated by C1INH following second order kinetics. 
Boundary Conditions 
 The pressure and velocity of the fluid are maintained at zero throughout the 
simulation. The initial concentrations of all species are set as in Table 3. The activated 
enzymes start at 0.1% of their corresponding inactivated forms. With the exception of 
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the area for clot modeling, the concentrations at the wall are set at zero. 
 Within the area of clot development, the boundary conditions are set such that: 
[ ] [ ][ ]
[ ] IXaM D
L
IX+K
VIIaTFIXk
=
x
IXa
7,9
7,9 −
∂
∂        (56) 
 
[ ] [ ][ ]
[ ] IXM D
L
IX+K
VIIaTFIXk
=
x
IX
7,9
7,9 −−
∂
∂        (57) 
 
[ ] [ ][ ]
[ ] XaM D
L
X+K
VIIaTFIXk
=
x
Xa
7,10
7,10 −−
∂
∂        (58) 
 
[ ] [ ][ ]
[ ] XM D
L
X+K
VIIaTFIXk
=
x
X
7,10
7,10 −−
∂
∂        (59) 
 
[ ] [ ] [ ]( )[ ]
tPA
tPaIatPAIIatPAC D
LENDOIak+IIak+k=
x
tPA
−−−−∂
∂     (60) 
 
 
For these equations, L is the length scale and chosen to be equal to the length (in the z-
direction) of the clot; D-- is the diffusion coefficient of the constituent of the subscript as 
listed in Table 2; the kinetic constants for the boundary conditions are listed in Table 4. 
The term ENDO represents endothelial cell concentration at the surface and is taken 
from Karsan and Harlan (2000): 
[ENDO] = 2.0 x 10
9          (61) 
 At the clotting surface, tissue factor associates with endogenous VIIa to form the 
TF-VIIa complex. As coagulation progresses, the action of thrombin also causes tissue 
factor and VIIa to associate and form TF-VIIa. In the work of Orfeo et al. (2005), 5 pM 
of tissue factor is introduced to synthetic plasma and the amount of TF-VIIa complex is 
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recorded. The curve is regenerated in Fig. 3, and scaled by a factor of 2 x 104 for the 
simulation. After 1500 seconds, the TF-VIIa level is set to zero. 
 For both simulations, gravity is not taken into account. Within the body, the 
directional effect of gravity changes due to several factors. As an example, if a person is 
standing, then gravity is working parallel to flow in arteries in the upper thigh. However, 
if a person sits or lies down, the gravity is working perpendicular to the direction of 
flow. Thus, if gravity were to be included it would call into question the physical 
position of a person. These models are neither developed nor intended for this level of 
specificity. It is also worth noting that the variation of position should not have a large 
impact on the formation and dissolution of a clot in a healthy subject. Therefore, gravity 
is not considered.  
MATLAB Computational Methodology 
 Uniform clot formation, growth, and dissolution are considered in one spatial 
dimension in 2 mm deep quiescent plasma exposed to a negatively charged surface and a 
thrombogenic pane. Thus, both the intrinsic and extrinsic pathways of coagulation are 
activated. A clot is considered to be formed when fibrin concentration meets or exceeds 
350 nM (adapted from Ovanesonov et al., 2002). The size of the clot is determined by 
tracking, in time, the regions within the domain that meet or exceed this level. The 
simulation is carried out over a period of 3000 seconds. 
 To model the information, the equations, initial conditions, and boundary 
conditions are non-dimensionalized according to: 
T
tt =∗           (62) 
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L
xx  = ∗           (63) 
( )0
 = 
=tC
CC
i
i
i ∗          (64) 
2= L
TDD ii∗           (65) 
( )0
 = 
=tC
TGG
i
i
i ∗          (66) 
The non-dimensionalized equations are then solved using the 'pdepe' routine in 
MATLAB with a mesh of δx* = 0.005, δt* = 0.001, T = 3000, and L = 0.002. 
Finite Domain Computational Methodology 
 Clot formation, growth, and dissolution are considered in a rigid cylindrical 
vessel 6 mm in diameter and 3 mm long. The pressure and velocity of the fluid are 
maintained at zero throughout the simulation. The calculations are done using the open 
source computational fluid dynamics program OpenFOAM. The software uses C++ and 
can be customized to reflect user-specific conditions. Additionally, the program comes 
with a mesh generation utility as well as post-processing tools to view results. 
 The solver was customized to reflect the biochemical equations described as well 
as the new constitutive equation for whole blood. The computations within the domain 
are carried out using a finite volume approach and a combination of two solution 
procedures. The first is the PISO (Pressure Implicit Splitting of Operators) algorithm, 
and it is used to solve time dependent equations. The second is the SIMPLE (Semi-
Implicit Method for Pressure Linked Equations), and it is used for steady state equations. 
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The relevant files can be seen in Appendix D. 
 The mesh is created using the blockMesh utility that comes with the software. In 
it, vertices are created and then connected in three dimensions. The faces are then given 
properties (such as wall, inlet, outlet, and for this work, clot) and the internal mesh is 
created according to assigned specifications.   Figures 4 and 5 show the mesh used in the 
calculation. Figure 6 shows the area subjected to the clotting boundary conditions.  
 The viscosity is calculated by using the fibrin concentration from the previous 
time step. As fibrin concentration increases past the critical level of clot development, 
the term is held constant. Thus, a clot is the maximum viscosity that the blood achieves.  
 The concentrations of the 28 biochemical factors have been set to a minimal level 
of 1 x 10-40 moles. Preliminary simulations showed values becoming negative numbers. 
As a result, this lower threshold was put in place to prevent such numerical discrepancies 
from happening.  
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RESULTS AND DISCUSSION 
 
 
Constitutive Equation for Whole Blood 
 The constants for the equation have been obtained as well as the function µ(c). 
The initial point µ(0) is redefined for the initial condition of fibrin concentration such 
that µ(0) = µ(7 x 10-9).  The equation for the function µ(c) is:     
( ) [ ] 0.14411.958 215 +Ia=cµ         (67) 
The remaining constants are set as α = 1540 and m = -0.277. Figure 7 shows the results 
of the model predictions (red) against experimental data (black) for whole blood. The 
behavior of the clot during formation (µ(150 x 10-9) ) is compared to the clot           
(µ(350 x 10-9 ) ) and whole blood (µ(7 x 10-9) ) in Fig. 8.  
 The coefficient of determination for the whole blood model is R2 = 0.9938. This 
shows that the whole blood model fits quite well to the experimental data. At low shear 
rates, the model is especially good at predicting the behavior of blood. Only at higher 
shear rates does a distinct and discernible difference become evident, and this is 
minimal. If flow were incorporated in the clotting model, these higher shear rates would 
fall outside the range for the size of the artery chosen (Kornet et al., 1999). 
MATLAB Results 
 The non-dimensionalized equations have been calculated and the results for 
thrombin production, fibrin production, and clot size are presented in Fig. 9, 10, and 11, 
respectively. Thrombin production is monitored because it is the main activation agent 
of fibrin. A peak in thrombin values should not precede a maximum in fibrin 
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concentration, but rather serve as a harbinger of the apex. The results for the intrinsic 
and extrinsic pathway are compared to those of modeling just the extrinsic pathway 
taken from Anand et al. (2008). Figure 11 has already been presented in LaCroix and 
Anand (2010).  
 Including the intrinsic pathway causes thrombin production to reach a higher 
concentration, but a longer time period is needed to reach it. With the intrinsic pathway a 
maximum value of 1.967 nM is reached at a time of roughly 150 seconds. After 
initiation, the highest value the extrinsic pathway reaches is 1.35 nM at a time of about 
75 seconds. Although, the extrinsic pathway peaks at an earlier time, it is worth noting 
that with the inclusion of the intrinsic pathway, a higher thrombin concentration is 
achieved at this same time. With the inclusion of the intrinsic pathway, maximum fibrin 
production achieves a higher value and occurs more quickly; a maximum concentration 
of 1723 nM is reached at roughly 300 seconds opposed to a peak of 1527 at roughly 400 
seconds when only the extrinsic pathway is considered. 
 Figure 11 tracks the size of the clot throughout the domain considered. The 
inclusion of the intrinsic pathway shows not only a larger clot being formed, but a faster 
dissolution of the clot. This can be attributed to the increased rate of PLA production due 
to the inclusion of factor XIIa. The increase in PLA results in a quicker breakdown of 
fibrin, and thus a faster rate of fibrinolysis. 
Finite Domain Results 
 The system of equations has been solved in a finite three dimensional domain 
with the boundary conditions stated. A clot is first developed at 440 seconds (the edges 
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of the clotting area reach a concentration level greater than 350 nM). At 475 seconds the 
entire clot boundary area has a concentration greater than 350 nM. Thus, a thrombus 
covers the entire clotting area. The thrombin level gradually increases until attaining a 
maximum value of 3.61 nM at a time of 528 seconds. After which, concentration drops 
off severely and stays at a low level for the remainder of the simulation. The peak level 
of thrombin within the clotting area with respect to time is shown in Fig. 12. The fibrin 
level within the clot area continues to increase until it reaches a maximum of 6123 nM at 
1035 seconds. At this point, the clot begins to lyse until its level drops below 350 nM at 
3685 seconds, signifying the dissolution of the clot at the wall. Figure 13 shows the 
maximum fibrin concentration within the clotting area for the duration of the simulation, 
and Fig. 14 shows the development of fibrin at 100 second intervals for the first 500 
seconds. As can be seen, the area of fibrin concentration is higher at the edges and is 
reduced towards the center. Thus the clot is propagating inward from the outside edge. 
Figure 15 shows the radial view of the blood vessel at the time of maximum 
concentration of fibrin. This view shows how far the clot extends radially into the blood 
vessel. 
 In order to corroborate the simulation, the fibrin and thrombin levels were 
compared to experimental tests. It is difficult to obtain in-vivo clotting data, especially 
when considering the specificity of the problem as modeled. Two different experimental 
tests were used for model corroboration. For thrombin level, the work of Butenas et al. 
(1999) is used. In the experiment, the peak thrombin level is measured at 420 seconds; 
the peak level of thrombin in the simulation is achieved at 528 seconds. Similar to the 
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fibrin performance, this is slightly slow, but still acceptable. It is worth noting that the 
simulation within the finite domain matches the curve more closely than those of the 
MATLAB simulations. 
For the fibrin, a study of temperature's effect on clotting done by Valeri et al. 
(1995) was used. The average clotting time for all subjects at a temperature of 37º C was 
348 ± 78 seconds. The simulation performed shows the first signs of clot at 440 seconds, 
and the entire area being clotted at 475 seconds. The performance is lags slightly behind 
the experimental work, but remains comparable.  
Sensitivity Analysis 
 A sensitivity analysis has been performed on prothrombin (factors Va and Xa). 
Prothrombin was chosen because it is the main activator of thrombin and would impact 
the production of fibrin through this relationship. For the original simulation, the 
activated factors are set to an initial level of 0.1% of their inactivated counterparts. The 
sensitivity analysis changed the initial level to 1%, and the impact on fibrin and 
thrombin production was recorded. The impact in relation to thrombin and fibrin 
production is presented in Fig. 16 and 17, respectively.  
 The sensitivity for the individual factors was also analyzed using: 
0.1M
M
P
P
=S normal
∂
∂
          (68) 
where the numerator is the difference in the maximum value of thrombin (or fibrin) 
achieved over the respective value in the original simulation. The denominator is the 
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change in the initial value of the individual factor over the initial value when it was at 
0.1%. The equation normalizes the impact of the factors in question. The results are 
presented in Table 5. Increasing the initial concentration of either factor increases the 
maximum amount of fibrin produced. The impact on thrombin, however, is quite 
different. While increasing the initial concentration of factor Xa sees a significant 
increase in maximum thrombin produced, the adjustment to factor Va actually causes a 
reduction in this value. Using eq 68, factor Xa has the greatest positive impact on fibrin 
and thrombin production. However, this gives an incomplete picture. 
 The most obvious shortcoming of the sensitivity analysis above is the lack of 
temporal effects. Adjusting Va and Xa alone reduces the time of peak thrombin 
production from 528 to 428 and 486 seconds, respectively. When increased together, the 
time of peak thrombin production is 427 seconds. The time it took to achieve the 
minimum fibrin concentration for a clot as well as maximum fibrin and thrombin 
production is presented in Table 6. Increasing either Xa or Va not only increases the 
maximum fibrin concentration, but also reduces the time it takes to achieve this value. 
By setting the initial value of Va or Xa at 1%, the time to clot is reduced from 440 to 75 
and 415 seconds, respectively. Increasing both values reduces this time further to 70 
seconds. Thus, raising the initial level of Va to 1%, either by itself or in conjunction with 
Xa, has a great impact on the time it takes to develop a clot. This small increase reduces 
clotting time to 1/6th of its initial value- a difference of more than 6 minutes.  
Grid Dependence 
 A preliminary grid dependence test has been done, but a more thorough 
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study is necessary before any conclusive statements can be made. The aim of this 
work was to extend the current biochemical model to include the intrinsic 
pathway of activation rather than carry out a numerical study upon each of the 
factors involved and how they are affected by alterations to the size of the mesh. 
Such a study would be large in scope and encompass a great deal of numerics as 
well as error calculations. 
For the grid dependence, the concentration of Va was monitored at a 
specific area, namely, the edge of the clot. Va was chosen because it is not one of 
the boundary values set and changes only due to reactions. A modest grid 
dependence test showed trivial changes in the concentration produced. A more 
drastic grid dependence test was completed by increasing the number of nodes for 
the mesh from 180 to 50,000. While the increase in nodes is by a factor of 270, 
the value of Va changes only by a factor of 3.3. These results show that a large 
jump in the number of nodes leads to a marginal increase in the concentration for 
factor Va. This modest addition is greatly offset by the huge expansion in 
computational time. 
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CONCLUSION AND FUTURE WORK 
 
This dissertation has presented a variety of work to add to the established 
literature with regards to modeling blood and coagulation.  
 A new constituent equation for blood as it behaves in large arteries has been 
presented. The model is shear-thinning. The viscosity of the fluid is based upon fibrin 
concentration, a feature never before included in other models. Thus the viscosity is 
progressively increased dependent upon how much fibrin is present. Though flow was 
not utilized in the subsequent clotting simulation, this new blood model can (and will) be 
incorporated in all future simulations. 
 The intrinsic pathway has been added to already existing mathematical model of 
coagulation. This involved the inclusion of the relevant components as well as their 
respective rate constants for activation and deactivation. The result was the addition of 
five additional factors and the expansion of the number of partial differential equations 
from 23 to 28.   
 The newly expanded model for coagulation was then solved in one spatial 
dimension as well as in a finite three dimensional domain similar to a medium sized 
artery, such as the femoral artery. Both the formation and subsequent fibrinolysis of the 
clot were presented. This three dimensional model can be easily expanded to include 
flow characteristics of blood, and if so desired, more clotting factors.  
 Finally, sensitivity analysis was completed on select factors within the clotting 
cascade. Prothrombin, was examined by elevating initial concentrations of factors Va 
43 
 
 
and Xa separately as well as together. The results show that increasing the initial level of 
Va greatly reduces the time necessary for the formation of the clot, while a heightened 
level of Xa increases maximum fibrin and thrombin concentrations.  
 While the new constitutive equation marks a step towards a progressively more 
viscous fluid during coagulation, it fails to capture the other properties of blood, namely 
elasticity and stress relaxation. A more accurate model would model blood as a complex 
mixture of all of its constituents. Similarly, a clot would be modeled as a mixture of 
platelets adhering to the fibrin mesh and include the other many varied components 
found within the intravascular compartment. 
The first step forward to a more accurate coagulation model is the inclusion of 
steady state flow. Though this is still not accurate with in-vivo conditions, it is the next 
step to a more complete model. Following the inclusion of steady state flow, the aspect 
of pulsatile flow can then be integrated. With this comes varying factors of pressure and 
velocity.  
After the inclusion of flow, the third major pathway, the platelet pathway, can be 
integrated into the model. Because platelets can be activated by shear stress, it is logical 
to include flow prior to the inclusion of the platelet pathway.  Its inclusion requires the 
mathematical characteristics of the interaction of both activated and inactivated platelets 
with each other as well as the other constituents being considered. Additionally, the 
model would consider the distribution qualities as well as platelet transport in flowing 
blood. 
 Finally, the finite dimensional model was calculated within a rigid cylinder. 
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Blood vessels expand and contract, and this may have a great effect on thrombus 
formation. Thus, the compliance of the blood vessel is an important aspect that would 
also need to be included for a fully complete simulation of blood coagulation.  
 In total, this dissertation marks a step, rather than a destination, on the long path 
towards a complete numerical simulation of blood coagulation. 
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APPENDIX A 
 
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Graphical representation of the clotting cascade that is modeled (the figure is 
modeled after a similar depiction from Rajagopal and Lawson, 2007). 
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Fig. 2. Separate graphical depiction of the clotting cascade modeled. Included are the 
complexes formed by various factors and ions.(LaCroix and Anand, 2010). 
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Fig. 3. Surface bound TF-VIIa concentration during thrombosis for 5 pM of added from 
tissue factor. The data is fitted to match the work of Orfeo et al. 2005. 
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Fig. 4. Front view of the mesh used in calculation. The center of the mesh is a 6x6 
square. Outside of this, each quadrant features a 6x6 section. There is a total of 18000 
nodes. 
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Fig. 5. A view of the mesh that includes all three dimensions. 
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Fig. 6. The area subjected to the clotting boundary conditions is shown in red. 
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Fig. 7. Whole blood experimental data from Chien et al. 1966 (black) versus model 
predictions (red). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
Fig. 8. Experimental data (black) from Chien et al. 1966 compared to µ(0) (red) to 
µ(150) (green) and µ(350)(blue line). The blue line represents the behavior of a clot and 
is 100 times more viscous than whole blood.  
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Fig. 9. Thrombin concentration at the clot surface versus time. The extrinsic model only 
is shown in red while the combined extrinsic and intrinsic pathways is modeled in black. 
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Fig. 10. Fibrin concentration at the clot surface versus time. The extrinsic pathway only 
is modeled in red while the combined extrinsic and intrinsic is modeled in black. 
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Fig. 11. Clot size versus time. The extrinsic pathway only is modeled in red. The 
extrinsic and intrinsic pathways combined are shown in black. (From LaCroix and 
Anand, 2010) 
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Fig. 12. The maximum value of thrombin on the clot surface for the first 1300 seconds. 
After 1300 seconds, the level drops to miniscule amounts. The maximum value of 3.61 
nM is achieved at 528 seconds. 
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Fig. 13. Fibrin concentration at the clot surface throughout the simulation. A maximum 
value of 6123 nM is achieved at 1035 seconds, at which point lysis begins.  
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Fig. 14. Evolution of the clot for the first 500 seconds. The scales for concentration are 
different for each figure and are presented in moles (rather than nM). The time at each 
(in seconds) is 100 (A), 200 (B), 300 (C), 400 (D), and 500 (E). Notice that between (D) 
and (E), the a concentration above 350 nM is achieved everywhere over the clotting 
surface.  
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Fig. 15. The radial size of the clot at peak fibrin concentration. 
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Fig. 16. Maximum thrombin concentration on the clot surface for different initial 
conditions. “Va 1%,” and “Xa 1%,” refer to the initial level of each being raised to 1%; 
and “XaVa 1%” represents both concentrations being at an elevated level. Increasing 
factor Va lowers the maximum amount of thrombin produced, however it reduces the 
time it takes to reach this maximum. By only increasing the initial level of Xa, a higher 
maximum is produced quicker, though not as quick as increasing Va. 
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Fig. 17. Maximum fibrin concentration at the surface of the clot for different initial 
conditions. “Va 1%,” and “Xa 1%,” refer to the initial level of each being raised to 1%; 
and “XaVa 1%” represents both concentrations being at a heightened level. The “Va 
1%” and “XaVa 1%” line follow the same path. While each increases the maximum 
fibrin produced, the biggest difference is in the initiation stage where an increased level 
of factor Va (either by itself or in conjunction with Xa) leads to a much quicker 
formulation of a clot. 
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APPENDIX B 
 
TABLES 
 
 
Table 1 
Kinetic constants used for the biochemical equations. “M” is for Michaelis-Menten, “F” 
is for first order and “S” is for second order. 
 
 
 
 
Equation Kinetics Parameters Source
26, 27 M  k11 = 0.0078 min
-1, K11M = 50 nM!! Gailani and Broze (1991)
26,47 S  h11A3 = 1.6 x 10-3 nM-1 min-1
!
Soons et al. (1987)
26, 49 S  h11L1 = 11.3 x 10-5 nM-1 min-1!! Scott et al. (1982)
33, 34 M  k9 = 11 min
-1, K9M = 160 nM! Sun and Gailani (1996)
33, 47 S  h9 = 0.0162  nM-1 min-1 Wiebe et al. (2003)
41,42 M  k8 = 194.4 min
-1, K8M = 112 000 nM! De Cristofaro and De Filippis (2003)
41 F  h8 = 0.222 min-1 ! Neuenschwander and Jesty (1992)
41 M  hC8 = 10.2 min-1 , HC8M = 12.6 nM Anand et al. (2008)
35 S  KdZ = 0.56 nM! Ahmad et al. (1989)
43, 44 M  k5 = 27.0 min
-1, K5M = 140.5 nM! Monkovic and Tracy (1990)
43 F  h5 = 0.17 min-1! Freyssinet et al. (1991)
43 M  hC5 = 10.2 min
-1, HC5M = 14.6 nM!! Solymoss et al. (1988)
36, 37 M  k10 = 2391 min
-1 , K10M = 160 nM Rawalasheikh et al. (1990)
36, 47 S  h10 = 0.347 nM-1 min-1! Wiebe et al. (2003)
36, 48 S  hTFPI = 0.48 nM-1 min-1! Wiebe et al. (2003)
38 S  KdW = 0.1 nM! Mann (1987)
39, 40 M  k2 = 1344 min
-1 , K2M = 1060 nM! Krishnaswamy et al. (1987)
39, 47 S  h2 = 0.714  nM
-1 min-1! Wiebe et al. (2003)
45,46 M  kPC = 39 min-1 , KPCM = 1060 nM! Tsiang et al. (1996)
45,49 S  hPC = 6.6 x 10-7 nM-1 min-1 Heeb et al. (1990)
50,51 M  k1 = 3540 min
-1  , K1M = 3160 nM! Tsiang et al. (1996)
50 M  h1 = 1500 min-1 , H1M = 250 000 nM! Diamond and Anand (1993)
53, 54 M  kPLA = 12 min-1, KPLAM = 18 nM! Madison et al. (1995)
53, 55 S hPLA = 0.096 nM-1 min-1 Kolev et al. (1994)
28, 29 M  k12 = 19.8 min-1, K12M = 7500 nM! Tankersly and Finlayson (1984)
28, 29 M  kkalli = 435 min-1, KkalliM = 780 nM! Tankersly and Finlayson (1984)
30, 31 M  kPreKA = 216
 
min-1, KPreKAM = 91 nM! Tankersly and Finlayson (1984)
30, 31 M  kPreKB = 2400 min-1, KPreKBM = 36,000 nM! Tankersly and Finlayson (1984)
29 F  h12 = 0.85 min
-1 Silverberg and Kaplan (1982)
29, 32 S  hCInh-12a = 2.2 x 10-4
 
nM-1 min Pixley et al. (1985)
29, 55 S  h !AP = 1.1 x 10
-5 nM-1 min-1! Pixley et al. (1985)
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Table 2 
Diffusion coefficients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Species Mol. Mass (Da) (cc/g) Diffusion coefficient (cm2/sec)
I 340000 0.723  3.10 x 10‐7
Ia ≈660,000 0.730  2.47 x 10-7
II 72000 0.719  5.21 x 10-7
IIA 37000 0.730  6.47 x 10-7
V 330000 0.730  3.12 x 10-7
Va 179000 0.730  3.82 x 10-7
VIII 330000 0.730  3.12 x 10-7
VIIIa 166000 0.730  3.92 x 10-7
IX 56000 0.730  5.63 x 10-7
Ixa 41000 0.730  6.25 x 10-7
X 56000 0.730  5.63 x 10-7
Xa 25000 0.730  7.37 x 10-7
XI 16000 0.730  3.97 x 10-7
XIa 80000 0.730  5.0 x 10-7
XII 80000 0.730 5.0 x 10-7
XIIa 108000 0.730 2.93 x 10-7
preK 84000 0.730 4.92 x 10-7
Kalli 84000 0.730 4.92 x 10-7
C1INH 105000 0.730 4.61 x 10-7
PC 62000 0.730 5.44 x 10-7
APC 60000 0.730 5.50 x 10-7
ATIII 58000 0.730 5.57 x 10-7
TFPI 40000 0.730 6.30 x 10-7
α1AT 51000 0.728 5.82 x 10-7
tPA 68000 0.730 5.28 x 10-7
PLS 92000 0.715 4.81 x 10-7
PLA 85000 0.715 4.93 x 10-7
α2AP 70000 0.720 5.25 x 10‐7
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Table 3 
Initial conditions for all factors. 
 
 
 
 
 
 
 
 
 
 
Species Initial Concentration (nM) Source 
I 7000 Mann et al. (1995) 
Ia 7.0  
II 1400 Mann et al. (1995) 
IIa 1.4  
V 20 Mann et al. (1995) 
Va 0.02  
VIII 0.7 Mann et al. (1995) 
VIIIa 0.0007  
IX 90 Mann et al. (1995) 
IXa 0.09  
X 170 Mann et al. (1995) 
Xa 0.17  
XI 30 Bungay et al. (2003) 
XIa 0.03  
XII 500 Brummel-Ziedens et al. (2004) 
XIIa 5  
preK 485 Brummel-Ziedens et al. (2004) 
Kalli 4.85  
C1INH 1625 Brummel-Ziedens et al. (2004) 
PC 60 Mann et al. (1995) 
APC .06  
ATIII 3400 Kalafatis et al. (1997) 
TFPI 2.5 Mann et al. (1995) 
α1AT 45000 Colman et al. (2001) 
tPA 0.08 Booth (1995) 
PLS 2180 Lijnen and Collen (2000) 
PLA 2.18  
α2AP 105 Colman et al. (2001) 
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Table 4 
Boundary condition parameters. 
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Table 5 
Sensitivity, S, to increased initial levels of activated factors V and X. The initial 
condition is set to 1% of their respective inactivated forms. The table uses equation 58 
from the text to find the impact of raising Va and Xa individually and together. 
  
Factor Ia IIa  
Va 0.004 -0.034 
Xa 0.006 0.039 
XaVa 0.0045 -0.025 
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Table 6 
Temporal effects of adjusting the initial level of Va and Xa. The time it takes to achieve 
the maximum concentration of fibrin and thrombin as well as reach a fibrin 
concentration of 350 nM (time to clot) is listed. For thrombin and fibrin, the maximum 
values are included in parentheses. All times listed are in seconds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factor Ia IIa Time to Clot 
Va 960 (6364) 428 (2.49) 75 
Xa 960 (6464) 486 (4.84) 415 
XaVa 960 (6369) 427 (2.46) 75 
Normal 1025 (6123) 528 (3.61) 440 
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APPENDIX C 
 
Model         Apparent Viscosity 
 
Walburn and Schneck (1976)   
     𝜇 = 𝐶!𝑒!!![𝑒!! !"#$!! ](𝛾)!!!! 
         
        C1=.00797      C2 = 0.0608 
        C3 = .00499    C4 = 14.585 
        H = 40%        TPMA = 25.9 
 
 
Carreau (Cho and Kensey, 1991)  𝜇 = 𝜇! + 𝜇! −  𝜇! [1+ 𝜆𝛾 !)]!!!!  
  
        λ= 3.313          n = 0.3568 
        µ0 = 0.56P   µ∞ = 0.0345P 
        P represents pressure 
 
Casson (Fung, 1997)      𝜇 = [ 𝜂!𝐽! !! + 2!!! 𝜏!!! ]!  𝐽!!!!  
         
       𝛾 = !!!     𝜏! = 0.1(0.625𝐻)!  
 
        𝜂 = 𝜂!(1− 𝐻)!!.! 
        η0 = 0.012P         H = 0.037 
 
        P  represents pressure 
 
 
Luo and Kang (1992)     𝜇 = !! =  𝜂! + 𝜂!𝛾!!! +  𝜏!𝛾!! 
 
        τy = 4.968     η1 = 4.076    
        η2 = 16.066 
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Refined Oldroyd-B (Anand and Rajagopal, 2004)  𝜇 =   !!!! !!!!  
 
        𝜆 =   ![!! !!!! ! !]!/! 
 
        𝜒 = 𝐾[!!!!!!    !!! !!!!!]! 
 
        n = 0.1372      η1= 0.1 Pa s-1     
       
       µ1 = 0.1611 N/m2     K = 58.0725 s-1    
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APPENDIX D 
 
 
Files are separated by bold font introducing them. There are four files presented. 
 
chemPimpleFoam.C : 
/*---------------------------------------------------------------------------*\ 
  =========                 | 
  \\      /  F ield         | OpenFOAM: The Open Source CFD Toolbox 
   \\    /   O peration     | 
    \\  /    A nd           | Copyright held by original author 
     \\/     M anipulation  | 
------------------------------------------------------------------------------- 
License 
    This file is part of OpenFOAM. 
 
    OpenFOAM is free software; you can redistribute it and/or modify it 
    under the terms of the GNU General Public License as published by the 
    Free Software Foundation; either version 2 of the License, or (at your 
    option) any later version. 
 
    OpenFOAM is distributed in the hope that it will be useful, but WITHOUT 
    ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or 
    FITNESS FOR A PARTICULAR PURPOSE.  See the GNU General Public License 
    for more details. 
 
    You should have received a copy of the GNU General Public License 
    along with OpenFOAM; if not, write to the Free Software Foundation, 
    Inc., 51 Franklin St, Fifth Floor, Boston, MA 02110-1301 USA 
 
Application 
    pimpleFoam 
 
Description 
    Large time-step transient solver for incompressible, flow using the PIMPLE 
    (merged PISO-SIMPLE) algorithm. 
 
    Turbulence modelling is generic, i.e. laminar, RAS or LES may be selected. 
 
\*---------------------------------------------------------------------------*/ 
 
#include "fvCFD.H" 
#include "singlePhaseTransportModel.H" 
#include "turbulenceModel.H" 
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// * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * // 
 
int main(int argc, char *argv[]) 
{ 
    #include "setRootCase.H" 
    #include "createTime.H" 
    #include "createMesh.H" 
    #include "createFields.H" 
    #include "initContinuityErrs.H" 
 
    Info<< "\nStarting time loop\n" << endl; 
 
    while (runTime.run()) 
    { 
        #include "readTimeControls.H" 
        #include "readPIMPLEControls.H" 
        #include "CourantNo.H" 
        #include "setDeltaT.H" 
 
        runTime++; 
 
        Info<< "Time = " << runTime.timeName() << nl << endl; 
 
        // --- Pressure-velocity PIMPLE corrector loop 
        for (int oCorr=0; oCorr<nOuterCorr; oCorr++) 
        { 
            if (nOuterCorr != 1) 
            { 
                p.storePrevIter(); 
            } 
 
//        Info<< "Velocity:" << endl; 
            #include "UEqn.H" 
//        Info<< "Chemical:" << endl; 
     #include<chemEqs.H>  
// Info<< "Viscoelasticity:" << endl; 
//     #include<viscoElasticity.H>  
 
 
            // --- PISO loop 
            for (int corr=0; corr<nCorr; corr++) 
            { 
                #include "pEqn.H" 
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            } 
 
            turbulence->correct(); 
        } 
 
//       if(runTime.write()){nuF.write();} 
        runTime.write(); 
 
        Info<< "ExecutionTime = " << runTime.elapsedCpuTime() << " s" 
            << "  ClockTime = " << runTime.elapsedClockTime() << " s" 
            << nl << endl; 
    } 
 
    Info<< "End\n" << endl; 
 
    return 0; 
} 
 
 
// 
***********************************************************************
** // 
 
Where, UEqn.H : 
 
 
nuST = ((nu0 - nuInf)/pow(scalar(1) + pow(lambdaMCM*mag(symm(fvc::grad(U))), 
m),n) + nuInf)/rho; 
 
nuF = min(nuST*(1 + nuStar*mag(CIa)/Threshold_CIa), 
nuST*nuStar*mag(CIa)/mag(CIa)); 
 
 
tmp<fvVectorMatrix> UEqn 
( 
    fvm::ddt(U) 
  + fvm::div(phi, U) 
  - fvm::laplacian(nuF, U) 
//  - fvc::div(Te)/rho           
 
//  + turbulence->divDevReff(U) 
); 
 
if (oCorr == nOuterCorr-1) 
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{ 
    UEqn().relax(1); 
} 
else 
{ 
    UEqn().relax(); 
} 
 
volScalarField rUA = 1.0/UEqn().A(); 
 
if (momentumPredictor) 
{ 
    if (oCorr == nOuterCorr-1) 
    { 
        solve(UEqn() == -fvc::grad(p), mesh.solver("UFinal")); 
    } 
    else 
    { 
        solve(UEqn() == -fvc::grad(p)); 
    } 
} 
else 
{ 
    U = rUA*(UEqn().H() - fvc::grad(p)); 
    U.correctBoundaryConditions(); 
} 
***********************************************************************
************ 
 
 
PEqn.H : 
 
 
U = rUA*UEqn().H(); 
 
if (nCorr <= 1) 
{ 
    UEqn.clear(); 
} 
 
phi = (fvc::interpolate(U) & mesh.Sf()) 
    + fvc::ddtPhiCorr(rUA, U, phi); 
 
adjustPhi(phi, U, p); 
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// Non-orthogonal pressure corrector loop 
for (int nonOrth=0; nonOrth<=nNonOrthCorr; nonOrth++) 
{ 
    // Pressure corrector 
    fvScalarMatrix pEqn 
    ( 
        fvm::laplacian(rUA, p) == fvc::div(phi) 
    ); 
 
    pEqn.setReference(pRefCell, pRefValue); 
 
    if 
    ( 
        oCorr == nOuterCorr-1 
     && corr == nCorr-1 
     && nonOrth == nNonOrthCorr 
    ) 
    { 
        pEqn.solve(mesh.solver("pFinal")); 
    } 
    else 
    { 
        pEqn.solve(); 
    } 
 
    if (nonOrth == nNonOrthCorr) 
    { 
        phi -= pEqn.flux(); 
    } 
} 
 
#include "continuityErrs.H" 
 
// Explicitly relax pressure for momentum corrector except for last corrector 
if (oCorr != nOuterCorr-1) 
{ 
    p.relax(); 
} 
 
U -= rUA*fvc::grad(p); 
U.correctBoundaryConditions(); 
 
***********************************************************************
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********** 
 
 
And chemEqs.H is : 
 
/*There will be set of following advection-diffusion equations: 
 
DC/Dt = D*ddC/dxx + G 
 
28 constituents:  
  
  
  
  
  
 CI  
 CIa  
 CII  
 CIIa 
 CV 
 CVa 
 CVIII 
 CVIIIa 
 CIX 
 CIXa 
 CX 
 CXa 
 CXI 
 CXIa 
 CPC 
 CAPC 
 CATIII 
 CTFPI 
 Calpha1AT 
 CtPA 
 CPLS 
 CPLA 
 Calpha2AP 
 CXII 
 CXIIa 
 CCInh 
 CCInh 
 CKalli   */ 
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//1  
    tmp<fvScalarMatrix> CIEqn 
    ( 
              fvm::ddt(CI) 
            + fvm::div(phi, CI) 
            - fvm::laplacian(DCI, CI) 
     + fvm::Sp((k1)*CIIa/(K1M + CI),CI) 
      
      
     //     - (-k1)*CIIa*CI/(K1M + CI) 
    ); 
 
     
    CIEqn().relax(); 
    solve(CIEqn); 
    CI = max(CI,  1e-40);     
    Info<< "CI min:" << min(CI).value() << endl; 
    Info<< "CI max:" << max(CI).value() << endl; 
//2 
    tmp<fvScalarMatrix> CIaEqn 
    ( 
              fvm::ddt(CIa) 
            + fvm::div(phi, CIa) 
            - fvm::laplacian(DCIa, CIa) 
     - (k1*CIIa*CI/(K1M + CI))  
     + fvm::Sp(h1*CPLA/(H1M + CIa),CIa) 
      
     //- (k1*CIIa*CI/(K1M + CI) - h1*CPLA*CIa/(H1M + CIa)   ) 
    ); 
    CIaEqn().relax(); 
    solve(CIaEqn); 
    CIa = max(CIa,  1e-40);     
    Info<< "CIa min:" << min(CIa).value() << endl; 
    Info<< "CIa max:" << max(CIa).value() << endl; 
//3 
    tmp<fvScalarMatrix> CIIEqn 
    ( 
              fvm::ddt(CII) 
            + fvm::div(phi, CII) 
            - fvm::laplacian(DCII, CII) 
     + fvm::Sp((k2)*CVa*CXa/(KdW*(K2M + CII)),CII)     
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     // - (-k2)*CVa*CXa*CII/(KdW*(K2M + CII))  
    ); 
    CIIEqn().relax(); 
    solve(CIIEqn); 
    CII = max(CII,  1e-40);     
    Info<< "CII min:" << min(CII).value() << endl; 
    Info<< "CII max:" << max(CII).value() << endl; 
//4 
    tmp<fvScalarMatrix> CIIaEqn 
    ( 
              fvm::ddt(CIIa) 
            + fvm::div(phi, CIIa) 
            - fvm::laplacian(DCIIa, CIIa) 
     - k2*CVa*CXa*CII/(KdW*(K2M + CII)) 
     + fvm::Sp(h2*CATIII,CIIa) 
      
     //   - (k2*CVa*CXa*CII/(KdW*(K2M + CII)) - h2*CIIa*CATIII) 
    ); 
    CIIaEqn().relax(); 
    solve(CIIaEqn);     
    CIIa = max(CIIa,  1e-40);     
    Info<< "CIIa min:" << min(CIIa).value() << endl; 
    Info<< "CIIa max:" << max(CIIa).value() << endl; 
//5 
    tmp<fvScalarMatrix> CVEqn 
    ( 
              fvm::ddt(CV) 
            + fvm::div(phi, CV) 
            - fvm::laplacian(DCV, CV) 
     + fvm::Sp((k5*CIIa/(K5M + CV)),CV) 
      
     //- (-k5*CIIa*CV/(K5M + CV)) 
    ); 
    CVEqn().relax(); 
    solve(CVEqn); 
    CV = max(CV,  1e-40);     
    Info<< "CV min:" << min(CV).value() << endl; 
    Info<< "CV max:" << max(CV).value() << endl; 
//6 
    tmp<fvScalarMatrix> CVaEqn 
    ( 
              fvm::ddt(CVa) 
            + fvm::div(phi, CVa) 
            - fvm::laplacian(DCVa, CVa) 
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     - (k5*CIIa*CV/(K5M + CV)) 
     + fvm::Sp(h5,CVa) 
     + fvm::Sp(hC5*CAPC/(HC5M + CVa),CVa) 
      
     //- (k5*CIIa*CV/(K5M + CV) - h5*CVa - hC5*CAPC*CVa/(HC5M + CVa) ) 
    ); 
    CVaEqn().relax(); 
    solve(CVaEqn); 
    CVa = max(CVa,  1e-40); 
    Info<< "CVa min:" << min(CVa).value() << endl; 
    Info<< "CVa max:" << max(CVa).value() << endl; 
//7 
    tmp<fvScalarMatrix> CVIIIEqn 
    ( 
              fvm::ddt(CVIII) 
            + fvm::div(phi, CVIII) 
            - fvm::laplacian(DCVIII, CVIII) 
     + fvm::Sp((k8*CIIa/(K8M + CVIII)),CVIII)    
      
     //- (-k8*CIIa*CVIII/(K8M + CVIII)) 
    ); 
    CVIIIEqn().relax(); 
    solve(CVIIIEqn); 
    CVIII = max(CVIII,  1e-40); 
    Info<< "CVIII min:" << min(CVIII).value() << endl; 
    Info<< "CVIII max:" << max(CVIII).value() << endl; 
//8 
    tmp<fvScalarMatrix> CVIIIaEqn 
    ( 
              fvm::ddt(CVIIIa) 
            + fvm::div(phi, CVIIIa) 
            - fvm::laplacian(DCVIIIa, CVIIIa) 
     - ((k8*CIIa*CVIII/(K8M + CVIII))) 
     + fvm::Sp(h8,CVIIIa) 
     + fvm::Sp(hC8*CAPC/(HC8M + CVIIIa) ,CVIIIa)     
      
     //- (k8*CIIa*CVIII/(K8M + CVIII) - h8*CVIIIa - hC8*CAPC*CVIIIa/(HC8M 
+ CVIIIa) ) 
    ); 
    CVIIIaEqn().relax(); 
    solve(CVIIIaEqn); 
    CVIIIa = max(CVIIIa,  1e-40); 
    Info<< "CVIIIa min:" << min(CVIIIa).value() << endl; 
    Info<< "CVIIIa max:" << max(CVIIIa).value() << endl; 
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//9 
    tmp<fvScalarMatrix> CIXEqn 
    ( 
              fvm::ddt(CIX) 
            + fvm::div(phi, CIX) 
            - fvm::laplacian(DCIX, CIX) 
     + fvm::Sp((k9*CXIa/(K9M + CIX)),CIX)   
      
     //- (-k9*CXIa*CIX/(K9M + CIX)) 
    ); 
 
    CIXEqn().relax(); 
    solve(CIXEqn); 
    CIX = max(CIX,  1e-40); 
Info<< "CIX min:" << min(CIX).value() << endl; 
Info<< "CIX max:" << max(CIX).value() << endl; 
 
//10 
    tmp<fvScalarMatrix> CIXaEqn 
    ( 
              fvm::ddt(CIXa) 
            + fvm::div(phi, CIXa) 
            - fvm::laplacian(DCIXa, CIXa) 
     - (k9*CXIa*CIX/(K9M + CIX)) 
     + fvm::Sp(h9*CATIII,CIXa) 
      
     //- (k9*CXIa*CIX/(K9M + CIX) - h9*CIXa*CATIII) 
    ); 
    CIXaEqn().relax(); 
    solve(CIXaEqn); 
    CIXa = max(CIXa,  1e-40); 
    Info<< "CIXa min:" << min(CIXa).value() << endl; 
    Info<< "CIXa max:" << max(CIXa).value() << endl; 
//11 
    tmp<fvScalarMatrix> CXEqn 
    ( 
              fvm::ddt(CX) 
            + fvm::div(phi, CX) 
            - fvm::laplacian(DCX, CX) 
     + fvm::Sp((k10*CVIIIa*CIXa/(KdZ*(K10M + CX))),CX)   
     
      
     //- (-k10*CVIIIa*CIXa*CX/(KdZ*(K10M + CX))) 
    ); 
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    CXEqn().relax(); 
    solve(CXEqn); 
    CX = max(CX, 1e-40); 
    Info<< "CX min:" << min(CX).value() << endl; 
    Info<< "CX max:" << max(CX).value() << endl; 
//12 
    tmp<fvScalarMatrix> CXaEqn 
    ( 
              fvm::ddt(CXa) 
            + fvm::div(phi, CXa) 
            - fvm::laplacian(DCXa, CXa) 
     - (k10*CVIIIa*CIXa*CX/(KdZ*(K10M + CX)) ) 
     + fvm::Sp(h10*CATIII,CXa) 
     + fvm::Sp(hTFPI*CTFPI,CXa)      //- (k10*CVIIIa*CIXa*CX/(KdZ*(K10M + 
CX)) - h10*CXa*CATIII - hTFPI*CTFPI*CXa ) 
    ); 
    CXaEqn().relax(); 
    solve(CXaEqn); 
    CXa = max(CXa, 1e-40); 
    Info<< "CXa min:" << min(CXa).value() << endl; 
    Info<< "CXa max:" << max(CXa).value() << endl; 
//13 
    tmp<fvScalarMatrix> CXIEqn 
    ( 
              fvm::ddt(CXI) 
            + fvm::div(phi, CXI) 
            - fvm::laplacian(DCXI, CXI) 
     + fvm::Sp((k11)*CIIa/(K11M + CXI) ,CXI) 
     + fvm::Sp((k12a)*CXIIa/(K12aM + CXI),CXI) 
      
     //- ((-k11)*CIIa*CXI/(K11M + CXI) + (-k12a)*CXIIa*CXI/(K12aM + CXI)   
) 
    ); 
    CXIEqn().relax(); 
    solve(CXIEqn); 
    CXI = max(CXI, 1e-40); 
    Info<< "CXI min:" << min(CXI).value() << endl; 
    Info<< "CXI max:" << max(CXI).value() << endl; 
//14 
    tmp<fvScalarMatrix> CXIaEqn 
    ( 
              fvm::ddt(CXIa) 
            + fvm::div(phi, CXIa) 
            - fvm::laplacian(DCXIa, CXIa) 
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     - (k11*CIIa*CXI/(K11M + CXI)) 
     - (k12a*CXIIa*CXI/(K12aM + CXI)) 
     + fvm::Sp(h11A3*CATIII,CXIa) 
     + fvm::Sp(h11L1*Calpha1AT,CXIa) 
     + fvm::Sp(hPCI11a*CCInh,CXIa) 
      
     //- (k11*CIIa*CXI/(K11M + CXI) + k12a*CXIIa*CXI/(K12aM + CXI) - 
h11A3*CXIa*CATIII - h11L1*CXIa*Calpha1AT - hPCI11a*CXIa*CCInh)    
    ); 
    CXIaEqn().relax(); 
    solve(CXIaEqn); 
    CXIa = max(CXIa, 1e-40); 
    Info<< "CXIa min:" << min(CXIa).value() << endl; 
    Info<< "CXIa max:" << max(CXIa).value() << endl; 
//15 
    tmp<fvScalarMatrix> CPCEqn 
    ( 
              fvm::ddt(CPC) 
            + fvm::div(phi, CPC) 
            - fvm::laplacian(DCPC, CPC) 
     + fvm::Sp((kPC*CIIa/(KPCM + CPC)),CPC) 
      
     //- ((-kPC)*CIIa*CPC/(KPCM + CPC)) 
    ); 
 
    CPCEqn().relax(); 
    solve(CPCEqn); 
    CPC = max(CPC, 1e-40); 
    Info<< "CPC min:" << min(CPC).value() << endl; 
    Info<< "CPC max:" << max(CPC).value() << endl; 
 
//16 
    tmp<fvScalarMatrix> CAPCEqn 
    ( 
              fvm::ddt(CAPC) 
            + fvm::div(phi, CAPC) 
            - fvm::laplacian(DCAPC, CAPC) 
     - (kPC*CIIa*CPC/(KPCM + CPC)) 
     + fvm::Sp(hPC*Calpha1AT/*/(KPCM + CPC)*/,CAPC) 
      
      
     //- (kPC*CIIa*CPC/(KPCM + CPC) - hPC*CAPC*Calpha1AT) 
    ); 
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    CAPCEqn().relax(); 
    solve(CAPCEqn); 
    CAPC = max(CAPC, 1e-40); 
    Info<< "CAPC min:" << min(CAPC).value() << endl; 
    Info<< "CAPC max:" << max(CAPC).value() << endl; 
//17 
    tmp<fvScalarMatrix> CATIIIEqn 
    ( 
              fvm::ddt(CATIII) 
            + fvm::div(phi, CATIII) 
            - fvm::laplacian(DCATIII, CATIII) 
            + fvm::Sp((h9*CIXa + h10*CXa + h2*CIIa + h11A3*CXIa + 
h12A3*CXIIa),CATIII) 
      
     //- ( -(h9*CIXa + h10*CXa + h2*CIIa + h11A3*CXIa + 
h12A3*CXIIa)*CATIII   ) 
    ); 
    CATIIIEqn().relax(); 
    solve(CATIIIEqn); 
    CATIII = max(CATIII, 1e-40); 
    Info<< "CATIII min:" << min(CATIII).value() << endl; 
    Info<< "CATIII max:" << max(CATIII).value() << endl; 
//18 
    tmp<fvScalarMatrix> CTFPIEqn 
    ( 
              fvm::ddt(CTFPI) 
            + fvm::div(phi, CTFPI) 
            - fvm::laplacian(DCTFPI, CTFPI) 
     + fvm::Sp((hTFPI*CXa),CTFPI) 
      
     //- ( -(hTFPI*CTFPI*CXa)   ) 
    ); 
    CTFPIEqn().relax(); 
    solve(CTFPIEqn); 
    CTFPI = max(CTFPI, 1e-40); 
    Info<< "CTFPI min:" << min(CTFPI).value() << endl; 
    Info<< "CTFPI max:" << max(CTFPI).value() << endl; 
//19 
    tmp<fvScalarMatrix> Calpha1ATEqn 
    ( 
              fvm::ddt(Calpha1AT) 
            + fvm::div(phi, Calpha1AT) 
            - fvm::laplacian(DCalpha1AT, Calpha1AT) 
     + fvm::Sp(hPC*CAPC,Calpha1AT) 
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     + fvm::Sp(h11L1*CXIa,Calpha1AT) 
      
     //- ( -hPC*CAPC*Calpha1AT - h11L1*CXIa*Calpha1AT    ) 
    ); 
    Calpha1ATEqn().relax(); 
    solve(Calpha1ATEqn); 
    Calpha1AT  = max(Calpha1AT, 1e-40); 
    Info<< "Calpha1AT min:" << min(Calpha1AT).value() << endl; 
    Info<< "Calpha1AT max:" << max(Calpha1AT).value() << endl; 
//20 
    tmp<fvScalarMatrix> CtPAEqn 
    ( 
              fvm::ddt(CtPA) 
            + fvm::div(phi, CtPA) 
            - fvm::laplacian(DCtPA, CtPA) 
 //    - (0) 
    ); 
    CtPAEqn().relax(); 
    solve(CtPAEqn); 
    CtPA = max(CtPA, 1e-40); 
    Info<< "CtPA min:" << min(CtPA).value() << endl; 
    Info<< "CtPA max:" << max(CtPA).value() << endl; 
//21 
    tmp<fvScalarMatrix> CPLSEqn 
    ( 
              fvm::ddt(CPLS) 
            + fvm::div(phi, CPLS) 
            - fvm::laplacian(DCPLS, CPLS) 
     + fvm::Sp(kPLA*CtPA/(KPLAM + CPLS),CPLS) 
     + fvm::Sp(kPLA12a*CXIIa/(KPLA12aM + CPLS) ,CPLS) 
      
     //- (-kPLA*CtPA*CPLS/(KPLAM + CPLS) - 
kPLA12a*CXIIa*CPLS/(KPLA12aM + CPLS)   ) 
    ); 
 
    CPLSEqn().relax(); 
    solve(CPLSEqn); 
    CPLS = max(CPLS, 1e-40); 
    Info<< "CPLS min:" << min(CPLS).value() << endl; 
    Info<< "CPLS max:" << max(CPLS).value() << endl; 
 
//22 
    tmp<fvScalarMatrix> CPLAEqn 
    ( 
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              fvm::ddt(CPLA) 
            + fvm::div(phi, CPLA) 
            - fvm::laplacian(DCPLA, CPLA) 
     - (kPLA*CtPA*CPLS/(KPLAM + CPLS)) 
     - (kPLA12a*CXIIa*CPLS/(KPLA12aM + CPLS)) 
     + fvm::Sp(hPLA*Calpha2AP,CPLA) 
      
     //- (kPLA*CtPA*CPLS/(KPLAM + CPLS) + 
kPLA12a*CXIIa*CPLS/(KPLA12aM + CPLS) - hPLA*CPLA*Calpha2AP  ) 
    ); 
 
    CPLAEqn().relax(); 
    solve(CPLAEqn); 
    CPLA = max(CPLA, 1e-40); 
    Info<< "CPLA min:" << min(CPLA).value() << endl; 
    Info<< "CPLA max:" << max(CPLA).value() << endl; 
 
//23 
    tmp<fvScalarMatrix> Calpha2APEqn 
    ( 
              fvm::ddt(Calpha2AP) 
            + fvm::div(phi, Calpha2AP) 
            - fvm::laplacian(DCalpha2AP, Calpha2AP) 
     + fvm::Sp((hPLA*CPLA + halphaAP*CXIIa),Calpha2AP) 
      
      
     //- (-(hPLA*CPLA + halphaAP*CXIIa)*Calpha2AP  ) 
    ); 
 
    Calpha2APEqn().relax(); 
    solve(Calpha2APEqn); 
    Calpha2AP = max(Calpha2AP, 1e-40); 
    Info<< "Calpha2AP min:" << min(Calpha2AP).value() << endl; 
    Info<< "Calpha2AP max:" << max(Calpha2AP).value() << endl; 
//24 
    tmp<fvScalarMatrix> CXIIEqn 
    ( 
              fvm::ddt(CXII) 
            + fvm::div(phi, CXII) 
            - fvm::laplacian(DCXII, CXII) 
     + fvm::Sp(k12/(K12M + CXII),CXII) 
     + fvm::Sp(kkalli*CKalli/(KkalliM + CXII),CXII) 
      
     //- (-k12*CXII/(K12M + CXII) - kkalli*CKalli*CXII/(KkalliM + CXII)   ) 
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    ); 
    CXIIEqn().relax(); 
    solve(CXIIEqn); 
    CXII = max(CXII, 1e-40); 
    Info<< "CXII min:" << min(CXII).value() << endl; 
    Info<< "CXII max:" << max(CXII).value() << endl; 
//25 
    tmp<fvScalarMatrix> CXIIaEqn 
    ( 
              fvm::ddt(CXIIa) 
            + fvm::div(phi, CXIIa) 
            - fvm::laplacian(DCXIIa, CXIIa) 
     - (k12*CXII/(K12M + CXII)) 
     - (kkalli*CKalli*CXII/(KkalliM + CXII)) 
     + fvm::Sp(h12,CXIIa) 
     + fvm::Sp(hPCI12a*CCInh,CXIIa) 
     + fvm::Sp(halphaAP*Calpha2AP,CXIIa) 
     + fvm::Sp(h12A3*CATIII,CXIIa) 
      
     //- (k12*CXII/(K12M + CXII) + kkalli*CKalli*CXII/(KkalliM + CXII) -
h12*CXIIa - hPCI12a*CXIIa*CCInh - halphaAP*CXIIa*Calpha2AP - 
h12A3*CXIIa*CATIII  ) 
    ); 
    CXIIaEqn().relax(); 
    solve(CXIIaEqn); 
    CXIIa = max(CXIIa, 1e-40); 
    Info<< "CXIIa min:" << min(CXIIa).value() << endl; 
    Info<< "CXIIa max:" << max(CXIIa).value() << endl; 
//26 
    tmp<fvScalarMatrix> CCInhEqn 
    ( 
              fvm::ddt(CCInh) 
            + fvm::div(phi, CCInh) 
            - fvm::laplacian(DCCInh, CCInh) 
     + fvm::Sp((hPCI12a*CXIIa + hPCI11a*CXIa),CCInh ) 
      
     //- ( -(hPCI12a*CXIIa + hPCI11a*CXIa)*CCInh  )  
    ); 
    CCInhEqn().relax(); 
    solve(CCInhEqn); 
    CCInh = max(CCInh, 1e-40); 
    Info<< "CCInh min:" << min(CCInh).value() << endl; 
    Info<< "CCInh max:" << max(CCInh).value() << endl; 
//27 
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    tmp<fvScalarMatrix> CPreKalliEqn 
    ( 
              fvm::ddt(CPreKalli) 
            + fvm::div(phi, CPreKalli) 
            - fvm::laplacian(DCPreKalli, CPreKalli) 
     + fvm::Sp(kPreKA*CXIIa/(KPreKAM + CPreKalli),CPreKalli) 
     + fvm::Sp(kPreKB*CXIIa/(KPreKBM + CPreKalli),CPreKalli) 
      
     //- (-kPreKA*CXIIa*CPreKalli/(KPreKAM + CPreKalli) - 
kPreKB*CXIIa*CPreKalli/(KPreKBM + CPreKalli) ) 
    ); 
    CPreKalliEqn().relax(); 
    solve(CPreKalliEqn); 
    CPreKalli = max(CPreKalli, 1e-40); 
    Info<< "CPreKalli min:" << min(CPreKalli).value() << endl; 
    Info<< "CPreKalli max:" << max(CPreKalli).value() << endl; 
//28 
    tmp<fvScalarMatrix> CKalliEqn 
    ( 
              fvm::ddt(CKalli) 
            + fvm::div(phi, CKalli) 
            - fvm::laplacian(DCKalli, CKalli) 
     - (kPreKA*CXIIa*CPreKalli/(KPreKAM + CPreKalli))  
     + fvm::Sp(hkalli,CKalli) 
      
      
     //- (kPreKA*CXIIa*CPreKalli/(KPreKAM + CPreKalli) + 
kPreKB*CXIIa*CPreKalli/(KPreKBM + CPreKalli) - hkalli*CKalli ) 
    ); 
    CKalliEqn().relax(); 
    solve(CKalliEqn); 
    CKalli = max(CKalli, 1e-40); 
    Info<< "CKalli min:" << min(CKalli).value() << endl; 
    Info<< "CKalli max:" << max(CKalli).value() << endl; 
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